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Summary 
Aromatase inhibitors (AI), the gold standard for treatment of postmenopausal women with 
hormone-sensitive breast cancer, add an additional burden to the risk of osteoporosis in the 
postmenopausal population. Individual variation in AI associated bone loss is related to clinical 
risk factors as well as genetic variations in drug metabolism. 
The aim of the study is to identify postmenopausal breast cancer patients at highest risk for AI- 
associated bone loss by utilizing clinical, biochemical and genetic parameters. In parallel, 
clinically meaningful patient reports were developed from a secure online genomics database 
resource, enriched during the study. 
This prospective study was conducted at the Tygerberg Hospital Breast Clinic in affiliation with 
Stellenbosch University. Postmenopausal women with endocrine sensitive breast cancer, aged 50 
to 80 years, were enrolled after obtaining informed consent. A baseline questionnaire documented 
demographic-, lifestyle- and medical history before commencing AI treatment. Clinical, 
biochemical and bone mineral density (BMD) measurements were obtained at baseline. 
Cytochrome P450 19A1 (CYP19A1) genotyping was performed using real-time polymerase chain 
reaction (PCR), and a screening algorithm applied to select patients for whole exome sequencing 
(WES). Results relevant to breast cancer diagnosis, comorbidities and treatment response were 
integrated into an adaptable report format for clinical application. Descriptive statistics were used 
to analyze the data. 
A total of 101 participants were recruited, with a mean age of 617 years. Thirty-two women 
fulfilled global criteria for bone protection at baseline [BMD T-score -2SD (n=18); BMD T-score 
-1.5SD to < -2SD with risk factors (n=14)]. In women with osteoporosis, significantly lower body 
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weight, body mass-, fat mass- and lean mass index were documented (p <0.001). Low vitamin D 
status was present in more than 90% of the cohort tested (n=95). After one year of AI treatment, 
72 patients remained in the study, of whom 10 (14%) experienced more than 5% bone loss at the 
lumbar spine. Genotyping for the CYP19A1 rs10046 in 72 patients revealed that patients with two 
copies of the A-allele are 7,37 times more likely to have a higher percentage bone loss at the total 
hip compared to those without this allele (CI of 1.101- 49.336, p=0.04). At the lumbar spine, 
CYP19A1 rs10046 AA homozygotes were 10.79 times more likely to have a higher percentage 
bone loss compared to patients with the GA or GG genotypes (CI of 1.771- 65.830, p=0.01). 
Extended genetic testing using Sanger sequencing and WES in the 10 patients with more than 5% 
bone loss supported the clinical findings. None of the 34 patients without bone loss at the lumbar 
spine at month 12 were homozygous for the functional CYP19A1 polymorphism. 
At baseline, a third of women fulfilled global criteria for bone protection. This highlights bone 
fragility associated with body composition variables of postmenopausal women in our 
predominantly Mixed Ancestry study cohort. Homozygosity for CYP19A1 rs10046 provides 
additional information for individual risk stratification to optimize bone health maintenance. New 
insights gained into the mechanisms impacting bone health merit continued health outcome studies 
embedded in routine clinical practice. 
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Opsomming 
Aromatase inhibitore (AI), die goue standaard vir die behandeling van postmenopausale vroue met 
hormoon-sensitiewe borskanker, dra by tot die risiko vir osteoporose in die postmenopausale 
bevolking. Individuele variasie in AI geassosieёrde beenverlies is verwant aan kliniese risiko 
faktore asook genetiese variasie in middel metabolism.   
Die doel van die studie is om postmenopausale borskanker pasiënte te identifiseer wat die hoogste 
risiko het vir AI geassosieërde beenverlies deur gebruik te maak van kliniese, biochemiese en 
genetiese maatreёls. In parallel hiermee, is klinies betekenisvolle pasiёnt verslae ontwikkel vanuit 
die aanlyn geslote genomiese databasis bron, wat verryk is tydens die studie. 
Die prospektiewe studie het plaasgevind by die Tygerberg Hospitaal Borskliniek, geaffilieёr met 
die Universiteit van Stellenbosch. Postmenopausale vroue met endokrien-sensitiewe borskanker, 
tussen die ouderdomme van 50-80 jaar, is opgeneem in die studie, na verkryging van ingeligte 
toestemming. ‘n Basislyn vraelys het demografiese- leefstyl- en mediese geskiedenis 
gedokumenteer voor die aanvang van AI behandeling. Kliniese, biochemiese en been mineraal 
digtheid mates is geneem met basislyn. Sitochroom P450 19A1 (CYP19A1) genotipering is 
uitgevoer deur die gebruik van reёl-tyd polimerase ketting reaksie (PCR) en ‘n siftingsalgoritme 
is toegepas om pasiёnte te selekteer vir heel eksoom volgorde bepaling (WES). Alle inligting is 
ingelees in ‘n geslote aanlyn genomiese bron, op ‘n aangaande basis. Resultate wat relevant is tot 
die borskanker diagnose, ko-morbiditeite en behandelingsrepons is geintegreer in ‘n aanpasbare 
verslag formaat vir kliniese toepassing. Beskrywende statistiek is gebruik om die data te analiseer. 
‘n Totaal van 101 deelnemers is gewerf, met ‘n gemiddelde ouderdom van 617 jaar. Twee-en-
dertig vroue het voldoen aan die internasionale kriteria vir been beskerming, met basislyn [BMD 
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T-telling -2SD (n=18); BMD T-telling -1.5SD to < -2SD met risiko faktore (n=14)]. In vroue met 
osteoporose is beduidend laer liggamsgewig, liggamsmassa-, vet massa- en spier massa indeks 
gedokumenteer (p <0.001). Lae vitamin D status was teenwoordig in meer as 90% van die kohort 
wat getoets is (n=95). Na een jaar van AI behandeling, het 72 pasiёnte oorgebly in die studie, van 
wie 14% (n=10) meer as 5% beenverlies ervaar het by die lumbale area. Genotipering van 
CYP19A1 rs10046 in 72 pasiёnte het geoon dat pasiёnte met twee kopiee van die A-alleel, 7,37 
meer geneig sal wees om n hoёr persentasie been verlies by die heup te hê in vergelyking met die 
sonder hierdie alleel (CI of 1.101- 49.336, p=0.04). By die lumbale area, was CYP19A1 rs10046 
AA homosigote, 10.79 meer geneig om ‘n hoёr persentasie beenverlies te hê in vergelyking met 
pasiёnte wat die GA or GG genotipes het (CI of 1.771- 65.830, p=0.01). Uitgebreide genetiese 
toetsing met Sanger volgorde bepaling en WES in die 10 pasiente met meer as 5% beenverlies, 
ondersteun die kliniese bevindinge. Nie enige van die 34 pasiënte wat geen been verlies getoon 
het by die lumbale area teen maand 12, was homosigote vir die funksionele CYP19A1 
polimorfisme nie. 
By basislyn het ‘n derde van vroue voldoen aan die internasionale kriteria vir beenbeskerming, 
wat die assosiasie van liggaamsamestelling in postmenopausale vroue van Gemengde Oorsprong, 
beklemtoon. Homosigote vir CYP19A1 rs10046 verskaf bykomende inligting wat in oorweging 
gebring kan word ten einde individuele risiko bepaling vir optimale beengesondheid te 
verwesenlik. Nuwe insigte in meganismes wat beengesondheid beinvloed, vereis voortgaande 
navorsing vasgelê binne ‘n kliniese opset. 
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Outline of the dissertation 
 
The thesis is presented in chapter format, starting with a general introduction (Chapter 1). A review 
of the clinical (Chapter 2) and genetic (Chapter 3) aspects relevant to the study is presented 
separately. In parallel with study recruitment, a database resource was developed to align the 
fragmented genetic research data with clinical service delivery information (Chapter 4). The 
characteristics of the study cohort was described at baseline (Chapter 5) and used to explore the 
role of genetics in aromatase inhibitor related bone outcomes, following 12 months of treatment 
(Chapter 6). A summative conclusion (Chapter 7) is provided as cohesion of the multidisciplinary 
research performed.  
 
This dissertation includes 2 original papers published in peer reviewed journals. The development 
and writing of the papers (published and unpublished) were the principal responsibility of myself 
and for each of the cases where this is not the case, a declaration is included in Appendix 1, 
indicating the nature and extent of the contributions of co-authors. 
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CHAPTER 1 
General Introduction 
Breast cancer is the most common malignancy in women worldwide (1). Endocrine therapy is an 
important modality in the treatment of postmenopausal women with hormone-sensitive breast 
cancer.  Several trials have documented a significant reduction of in-breast recurrence and contra-
lateral breast cancer, as well as a reduction in the risk of distant metastases with the use of 
aromatase inhibitors (AI)(2-4). The prolonged breast cancer survival rates necessitates attention to 
quality of life, most notably prevention of treatment-related bone health impairment (6).   
Physiological changes in older women increase the risk of developing osteoporosis. The bone side 
effects of AIs add an additional burden of osteoporosis to an already  at-risk population (5, 6), 
which accentuates the importance of maintaining bone health. In the post-menopause, estrogen 
production predominantly originates from adipose tissue, the adrenal glands, smooth muscle, and 
bone (7). AIs decrease estrogen levels by preventing estrogen production via aromatization of 
androgen precursors in peripheral tissues (6, 8). These low residual estrogen levels in healthy 
postmenopausal women are important in preserving bone health (9, 10).  
Treatment-related bone loss in  breast cancer may be different to the bone loss typically 
experienced in the postmenopausal woman (11). At the start of menopause, yearly bone loss is 
estimated at 2% annually; it plateaus at about 1% during the 2nd decade after menopause and 
beyond. However, the bone loss associated with AIs in postmenopausal women was estimated to 
be  >2.5% per annum (6, 12). Although breast cancer patients treated with AIs are at increased risk 
of bone loss and fracture, only 25 – 50% of postmenopausal AI users develop bone loss and 
fractures (13). This vulnerable subgroup is undefined and risk factors remain unclear. The 
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American Society of Clinical Oncology and the UK Expert Group have established osteoporosis 
prevention and treatment algorithms for women initiating treatment with AIs (14). These involve 
close follow-up of bone mineral density (BMD) and a more aggressive pharmacotherapy compared 
to healthy postmenopausal women with osteoporosis (15).   
BMD,  an assessment of mineral content at specific skeletal sites is measured by dual energy X-
ray absorptiometry (DXA) (16). DXA is accurate, non-invasive and can detect silent vertebral 
fractures and calculate body composition. It is also utilized to estimate BMD changes over time 
and evaluate response to therapy (17-19). As BMD decreases, the risk of fracture increases 
exponentially,  two- to three-fold with every standard deviation (SD) decline in BMD (20, 21). 
Conventional risk factors for osteoporosis include  modifiable and non-modifiable risk factors 
(22). Age, sex, genetic predisposition and ethnicity signify the most important non-modifiable 
factors. Adjustable factors such as low body weight, an inactive lifestyle, poor calcium diet and 
deficient vitamin D levels, smoking and excess alcohol use, may also impact bone density 
considerably. In women of all ethnicities, body weight is one of the most significant determinants 
of BMD at most skeletal sites (22, 23).  
Bone health should be assessed by utilizing a mixture of parameters. These include the clinical 
risk factors, BMD measurement and biochemical markers of bone turnover. Bone formation 
biomarkers include serum bone specific alkaline phosphatase and osteocalcin, as well as 
parameters of bone resorption e.g. urine deoxypyridinoline, serum C terminal telopeptide. These 
markers of bone turnover can forecast postmenopausal bone loss rates and assess fracture risk 
independent of BMD. These indicators of bone turnover are more sensitive than BMD and changes 
can be identified within 4-6 months. In the osteoporosis-treatment studies (with alendronate, 
risedronate, raloxifene), bone turnover markers appear to have a stronger correlation with fracture 
Stellenbosch University  https://scholar.sun.ac.za
3 
 
risk reduction than BMD (24, 25). This supports the use of bone turnover markers as substitutes 
for fracture risk reduction.  
Osteoporosis has serious clinical and health systems implications. The addition of AIs as endocrine 
treatment of breast cancer compounds the problem. The prevalence of BMD and fractures have 
been described internationally, but data amongst diverse populations in Southern Africa is limited 
to black and white patients (26- 28). Expansion of knowledge in other ethnicities will optimize 
strategies towards prevention and management of osteoporosis as well as for the post-menopausal 
woman treated for breast cancer (29).  
The causal mechanism of cancer treatment induced bone loss remains undefined.  The aromatase 
enzyme plays a critical role in bone health. Pathogenic mutations in the Cytochrome P450 
(CYP450) CYP19A1 gene cause decreased BMD due to a significant effect on enzyme activity 
(30-32). Genetic polymorphisms in the aromatase gene have been associated with estrogen levels 
and bone mass in healthy postmenopausal women and men (33). Signiﬁcant associations have 
been reported between several  polymorphisms in the CYP19A1 gene and bone health in 
postmenopausal women (33). Careful selection of clinically relevant single nucleotide 
polymorphisms (SNP) for pharmacogenetic studies is important and functionality should ideally 
be confirmed using in vitro studies as demonstrated for CYP19A1 rs10046 (34). This SNP is 
associated with raised estrogen levels because of elevated enzyme activity, expected to be 
beneficial for bone health but detrimental to cancer outcomes. Advances in pharmacogenetics, 
moving from SNP genotyping testing to next generation sequencing, covering the entire gene, 
could overcome the limitations of incomplete genotyping, which may lead to incorrect risk 
allocation of polymorphic alleles. 
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To determine the genetic contribution to AI treatment-related bone loss, a comprehensive 
assessment of established baseline characteristics is necessary. International consensus 
recommends that all women with endocrine sensitive breast cancer should have a baseline 
osteoporosis risk assessment, prior to starting an AI (35, 36). A thorough evaluation allows for 
individualized risk stratification and bone protective measures to be introduced as clinically 
indicated (37, 38). Bone protective measures as globally agreed, suggest that all women with a 
BMD T-score of -2 SD or less at any measured site, should be protected with bone directed therapy. 
Furthermore, patients with a BMD T-score of -1.5 SD or less with additional bone risk factors, 
should also be considered for treatment (36). These include women above 65 years of age, 
smoking, low body weight, a family or personal history of fractures as well as a course of steroid 
therapy of longer than a 3-month period. Recommended pharmacological therapy for these at-risk 
patients includes vitamin D and calcium supplementation especially if nutritional intake is 
insufficient. Antiresorptive therapy with bisphosphonates are recommended in patients with a 
baseline T score of <−2.0 or two or more clinical risk factors for fracture (5). 
There is significant individual variation in AI associated bone loss, which could be related to 
clinical factors such as age, menopausal status, years since menopause and body mass index 
(BMI). It is clear that individual vulnerability to AI side effects differs and this unpredictability 
may partly be explained by diverse genetic profiles (39). Breast cancer pharmacogenetics are 
evolving with utilization of whole exome sequencing (WES) to identify genetically predisposed 
patients for AI adverse bone effects.  In this study, the clinical value of AI pharmacogenetics as an 
additional bone risk factor postmenopausal breast cancer patients on AIs, was explored within the 
context of a pathology supported genetic testing algorithm developed in South Africa (40). 
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Aim 
The aim of the study is to employ clinical, biochemical and genetic measures to improve the 
understanding of the pathophysiology of treatment-induced bone loss. An examination into the 
impact of AIs on bone health in a multi-ethnic postmenopausal cohort with endocrine responsive 
breast cancer resident in the Western Cape Province of South Africa was undertaken.  
The goal is to identify a subgroup of women at highest risk of severe side effects, for effective 
implementation of preventive measures at the onset of treatment or by early modification of 
management. 
Integrating research on AI pharmacogenetics with established clinical and biochemical bone loss 
risk factors could lead to improved individualized cancer care and simultaneously enrich an onco-
genomic database resource, beyond a single study objective. 
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Abstract 
Breast cancer, as the most common malignancy in women, remains a major public health issue 
despite countless advances across decades. Endocrine therapy is the cornerstone of treatment of 
the hormone sensitive subtype of breast cancer. The use of aromatase inhibitors (AIs) in the post-
menopausal women has extended the survival beyond that of Tamoxifen, but harbours a subset of 
side effects, most notably accelerated bone loss. This, however, does not occur in all women 
undergoing treatment. It is vital to identify susceptible patients early, to limit such events, employ 
early treatment thereof or to alter drug therapy. International trials on AIs, predominantly 
performed in North American and European females, provide little information on what to expect 
in women in developing countries. Here, surgeons often prescribe and manage endocrine therapy. 
The prescribing surgeon should be aware of adverse effect of endocrine therapy and be able to 
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attend to side effects. This review highlights clinical and biochemical factors associated with 
decrease in bone mineral density in an, as yet, unidentified subgroup of post-menopausal women.  
In the era of personalised medical care, appropriate management of bone health by surgeons based 
on these factors becomes increasingly important. 
Abbreviations  
AIs - Aromatase inhibitors; ATAC- Arimidex Tamoxifen, Alone or in Combination; AEs- adverse 
effects; BMD - Bone mineral density; BMI – Body mass index; BS-ALP- bone-specific alkaline 
phosphatase; BIG 1-98- Breast International Group 1-98; CYP 19- cytochrome P450 enzyme; CR- 
clinical response; CTX- C terminal telopeptide; DNA- deoxyribonucleic acid; DXA -dual-energy 
x-ray absorptiometry; ER- estrogen receptor; FRAX- Fracture Risk Assessment Tools; HER 2- 
human epidermal growth factor 2; IOF- International Osteoporosis Foundation; IES Intergroup 
Exemestane Study; LVA- Lateral vertebral assessment; NCIC CTG-National Cancer Institute of 
Canada Clinical Trialist Group; NTX- cross-linked N-telopeptides of bone type I collagen; NOF- 
National Osteoporosis Foundation; NHANES- National Health and Nutrition Examination 
Survey; PTH- parathyroid hormone; PR- progesterone receptor; RANKL- receptor activator of 
NF-κB ligand; SNPs- single nucleotide polymorphisms; SDs- standard deviations; 25(OH) vitamin 
D- 25 hydroxy vitamin D; WHO- World Health Organisation 
Introduction 
Breast cancer is the most common female cancer, globally (1). In developing countries, it has 
replaced cervical cancer as the leading cause of cancer death in women (1). These patients ideally 
should  be managed in multidisciplinary teams that coordinate surgical treatment in conjunction 
with the modalities  of chemotherapy, irradiation, endocrine therapy, and biological therapy (2). 
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In developing countries, such as South Africa, this is often available only in major centres and 
mostly in tertiary hospitals affiliated with universities (3). 
Determination of the molecular receptor status of tumours is standard in breast cancer 
classification. Routine testing for receptors in breast cancer includes the estrogen receptor (ER), 
progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2) (2). 
Hormone-receptor sensitive breast cancer is the most common breast cancer subtype and endocrine 
therapy is the cornerstone of systemic treatment (4).  
Women with hormone receptor–positive disease have an excellent 5-year survival (5). Endocrine 
therapy in the adjuvant setting for the post-menopausal status consists of treatment with Tamoxifen 
or Aromatase inhibitors (4). Endocrine manipulation has systemic side effects. It is important to 
take cognizance of these and accurately quantify the potential for long-term morbidity (6). 
In premenopause, ovaries are the principal source of estradiol. In post menopause, ovaries cease 
to produce estrogen and circulating estrogen levels fall precipitously. Extragonadal sites such as 
adipose tissue, breast, bone, vascular epithelium and brain produce estrogen locally from C19 
steroid precursors via the aromatase cytochrome P450 enzyme. Circulating estrogen levels 
therefore do not accurately reflect concentrations in local tissue, where estrogen acts in a paracrine 
or intracrine fashion (7). In bone in particular, local estrogen production slows postmenopausal 
bone loss (7). 
Bone health  
Osteoporosis is characterized by compromised bone strength that predisposes to an  increased risk 
of fracture (8). Osteoporotic fractures occur in nearly 40% of post-menopausal women. 
Menopausal women experience a sustained doubling of bone turnover (8) due to estrogen 
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withdrawal and a subsequent increase in bone resorption. An accelerated loss of BMD of 1–3% 
per year at the spine and 1–2% per year at the hip has been observed in the first 7 years after the 
onset of the menopause. 
This weakening of the bone structure decreases resistance to low-energy trauma and coupled with 
a low BMD increases bone fragility and fracture risk (9). Major risk factors for osteoporosis 
comprise: age, female sex, a personal history of fracture as an adult, a history of a fragility fracture 
in a first-degree relative, low body weight, current smoking and excessive alcohol consumption, 
and use of corticosteroids (10). Other contributing factors are: excess height, poor general health 
and certain endocrine and systemic conditions. Poor depth perception and the use of drugs like 
benzodiazepines increase the risk of falling and so add to the fracture incidence. 
The most common sites of fragility fractures are: vertebrae, femoral neck, and distal radius (8). 
Methods used to assess fracture risk include bone mineral density (BMD), biochemical bone 
markers and the Fracture Risk Assessment Tools utilized in countries or regions with known hip 
prevalence figures. 
Bone Mineral Density 
Bone mineral density (BMD) is an assessment of the mineral content in key skeletal regions (11). 
It is measured with dual x-ray absorptiometry and expressed in absolute terms as grams of mineral 
per square centimeter scanned (g/cm2). The T-score is the number of standard deviations that a 
patient’s bone mineral density value is above or below the reference value for a healthy thirty-
year-old adult.  
Results are expressed as standard deviations (SDs) from age- and sex-matched standards (Z score) 
or from the population mean peak bone mass (T score). The reference range recommended by the 
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International Osteoporosis Foundation (IOF), World health Organisation (WHO) and National 
Osteoporosis Foundation (NOF) for calculating the T-score is the National Health and Nutrition 
Examination Survey (NHANES) III reference database for femoral neck measurements in 
Caucasian women aged 20–29 years (12). Fracture risk increases roughly twofold for every 
standard deviation below the mean for a young adult. The WHO defines normal bone mass as T> 
-1.0, with osteopenia being T < -1.0 and Z > -2.5, and osteoporosis T <-2.5. Each SD represents a 
difference of 10%-15% in BMD. A T score of < -2, 5 is indicative of a 25% loss from peak bone 
mass. Fracture risk increases exponentially with lower BMD. For T scores of -1.0,-2.0, and -3.0, 
the relative risks of fracture are 1.7-, 3.4-  and 6.8-fold, respectively (8).  
DXA measured BMD is accurate and reproducible. It uses x-rays to assess BMD by area (not 
volume). The radiation dose is approximately one-tenth of a standard chest x-ray. Patients should 
have repeat BMD measured by the same machine and by the same operator, to minimize error (8). 
It is the only bone density test that is currently useful for assessment of BMD changes over a time 
period and for determining the response to therapy (13).  
Fracture Risk Assessment Tools (FRAX) 
BMD provides the cornerstone for the diagnosis of osteoporosis, but it cannot be used in isolation 
as a determinant for the initiation of therapy (12). The WHO’s Fracture Risk Assessment Tool 
(FRAX) is a risk prediction model that employs the femoral neck BMD as measured by DXA and 
includes clinical factors for bone loss. It estimates the 10-year probability of hip and other major 
osteoporotic fractures (spine, humerus and forearm). Clinical factors include: country or 
geographic region , the patient’s ethnic origin, age, sex, weight, height, prior fragility fracture, 
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parental history of hip fracture, current smoking, excess alcohol intake, long-term use of oral 
glucocorticoids, rheumatoid arthritis, and secondary osteoporosis (11).  
FRAX can be calculated for 4 ethnicities (white, Hispanic, Asian, and black) in a sex- and 
geographic-specific manner (8). It allows entry of ages 40 to 90 years; there is no validation of 
FRAX in younger or older patients. FRAX cannot be used to monitor therapy as it considers only 
femoral neck bone density in the calculation of risk and allows only yes / no input rather than 
gradations of secondary risk factors. In the United States, the National Osteoporosis Foundation 
recommends treatment of patients with a FRAX-calculated 10-year fracture probability of >3% 
for hip fracture and >20% for major osteoporotic fracture (11). 
A similar web-based tool, the FORE 10-Year Fracture Risk Calculator 
(http://riskcalculator.fore.org), closely aligns with the US regional data from the WHO-FRAX 
model offering similar risk estimates for men and women older than 45 years. FORE also allows 
entry of glucocorticoid dosing; allows information on spine fracture; and adds a graphic display 
showing low, moderate, or high 10-year fracture risk for use in patient education (8). 
Biomarkers of Bone Turnover  
The common use of aromatase inhibitors led to in an increased focus on cancer treatment-induced 
bone loss. Bone strength is a function of BMD and bone quality. Bone quality describes the set of 
characteristics that influence bone strength independently of BMD and include structural and 
material properties. Bone turnover is a function of the bone renewal process in which old or 
damaged bone is resorbed (bone resorption) and new bone is created (bone formation). Normally 
bone resorption and formation is tightly balanced to ensure that bone mass and quality is 
maintained. Excess resorption and sustained increases in bone turnover not only result in decreased 
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BMD, but may also adversely affect bone architecture and quality. These qualitative changes may 
decrease bone strength independent of BMD. Biomarkers are used to assess the rate of bone 
turnover and can thus provide information on bone quality. Combining BMD and bone markers 
allows for the identification of a subcategory of individuals at an increased risk of hip fracture 
compared to those identified by each test in isolation (14).  
The role of estrogen in bone health 
Estrogen plays an integral part in bone metabolism in women and is fundamental in the 
pathogenesis of osteoporosis in postmenopausal women. The bone loss associated with estrogen 
deficiency is a complex and multidimensional process (15). Estrogen is a systemic inhibitor of 
bone resorption by complex measures on bone cellular level (16). The reduction of serum 
oestradiol at the onset of the menopause leads to a negative balance at the bone remodelling unit 
level (17). The mechanisms by which estrogen regulates bone remodelling are not fully understood 
but estrogen is thought to affect osteoclastogenesis and osteoclast functioning through its effects 
on local cytokines and growth factors.  
Endocrine therapy 
There are two distinct subtypes of estrogen receptors, namely ER- and ER-. Tamoxifen has 
been used in the treatment of endocrine sensitive breast cancer for decades and it is the benchmark 
against which newer drugs are measured.  Tamoxifen acts as a pure antagonist on ERα in breast 
tissue, resulting in a decrease in breast cancer cell proliferation (19). Conversely, it acts as an 
agonist on the estrogen receptor β expressed in bone and brain thereby promoting estrogen 
effects in these organs. This selective agonist effect of Tamoxifen in bone thus protects women 
Stellenbosch University  https://scholar.sun.ac.za
19 
 
against accelerated postmenopausal bone loss attributable to cessation of ovarian estrogen 
production (20).  
An overall 19% reduction in the incidence of fractures was seen in postmenopausal women 
receiving Tamoxifen therapy for a median of 5.75 years (18). Tamoxifen use in the switch trials 
as well as extended duration of treatment beyond 5 years are well documented (19, 20).  
Aromatase inhibitors heralded a new strategy in the treatment of breast cancer. These agents are 
without the estrogenic effects and have an improved side effect profile compared to Tamoxifen 
(21). Today, it constitutes the gold standard in treatment of endocrine responsive breast cancers in 
postmenopausal women. 
The use of aromatase inhibitors (AI) in post-menopausal patients is well-established.  Several trials 
have documented a significant reduction of in-breast recurrence and contra-lateral breast cancer, 
as well as a reduction in the risk of distant metastases (22, 23). The third-generation aromatase 
inhibitors demonstrate greater efficacy and superior overall safety in the adjuvant treatment of 
women with hormone receptor-positive breast cancer, compared with the selective estrogen 
receptor modulator Tamoxifen (24, 25). 
The near total suppression of oestrogen production by aromatase inhibitors has focused research 
on the aggravation of symptoms of menopause such as hot flashes and cardiovascular disease and 
has also raised significant concern regarding potential worsening of bone loss and the incidence of 
fragility fractures (26). 
Bone loss and fracture 
Aromatase inhibitors are the drugs of choice in post-menopausal breast cancer patients with 
endocrine responsive tumours. However, aromatase inhibitors enhance bone turnover and result in 
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the loss of bone mass (27).  The general population risk factors for osteoporosis apply to breast 
cancer patients. However, cancer treatment causes additional bone loss that could increase the risk, 
above that seen in cancer-free women.  
The level of bone loss and fracture risk is directly related to the further suppression of already low 
post-menopausal estrogen levels. In post-menopausal women, AIs decrease the serum levels of 
oestrogen beyond physiological levels and it is expected that bone loss would be augmented (28, 
29). The ATAC (Arimidex, Tamoxifen, alone or in combination) bone sub-protocol confirmed 
that adjuvant Anastrozole therapy can lead to accelerated bone loss for postmenopausal women 
with early breast cancer (30), compared to the bone-protective effect seen with Tamoxifen. This 
confers a 2- to 3-fold higher risk of fractures versus women receiving Tamoxifen.  Annual rates of 
bone loss from AI treatment range from 3%-4% at the spine and 1%-2% at the hip (31).  Hip 
fractures, associated with greater morbidity than all other osteoporotic fractures combined, did not 
differ between treatment groups, even with follow-up extending beyond the 5-year treatment 
period. The relative increase in fractures in the Anastrozole group remained constant over the 5-
year treatment period but was not evident in year 6 (32, 33). 
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Trials  Intervention  BMD changes (%) p value Fracture 
rate (%) 
ATAC (6) Arimidex 
  
Tamoxifen, alone or in combination 
Hip:   - 7.24   
Spine: - 6.08  
Hip:  0.74 
Spine:  2.77 
<0.01 11  
 
7.7 
NCIC 
CTG 
MA.17/BI
G 1–97(6) 
Letrozole (post Tamoxifen) 
 
Placebo 
Hip:    -3.4   
Spine: – 4.1  
Hip:  2 
Spine: 1.0 
0.009 5.3  
 
4.6 
IES (6, 24) Exemestane post Tamoxifen 
 
Tamoxifen (continued) 
Hip:   -2.9 
Spine – 3.9  
Hip:  -1 
Spine - 0.6 
<0.001 7   
 
4.9 
Gonelli (6) 
 
Tamoxifen 
 
Exemestane (post Tamoxifen) 
 
Hip:   - 2.01  
Spine – 3.0  
Hip:  0 
Spine: 0.0 
<0.01 Not 
available 
BIG 1-98  
(6, 17) 
Letrozole (L) 
Tamoxifen (T)  
Not available 
 
0.002 5.7 
4.0 
 
Table 2.1: Impact of endocrine therapy on BMD in postmenopausal women with breast cancer 
Most of the large clinical trials have evaluated bone loss rates of AI therapy and reported 
significant bone loss at lumbar spine and hip. (Table 2.1) The rates of bone density change after 1 
year of AI treatment ranged from -1.66 % to -7.40 %; a wide variation depending on the baseline 
characteristics of the patients studied (34).  
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Many trials lack data on baseline risk factors for fracture, including, older age, prior fracture, and 
other co-morbidities, as well as the longer-term effect on bones. The objective of treatment is not 
only to ensure cancer-free survival, but to limit detrimental effects of therapy (6).  
Bone turnover 
Measurement of bone turnover markers can be used to examine changes in bone turnover in the 
short term (35). ATAC and MA17 (20, 36) indicated  statistically significant increases in both 
bone formation markers (e.g. osteocalcin) and bone resorption markers (e.g. cross-linked N-
telopeptides of bone type I collagen [NTXs]) over the first 3 to 24 months of treatment of AI 
therapy. Studies examining AI-induced bone marker changes suggest a disparity between 
resorption and formation, leading to a net bone loss and increased fracture risk. Bone turnover 
marker profiles may be clinically useful in identifying those at highest fracture risk who require 
early intervention with anti-resorptive agents or potentially a change in treatment (35). The bone 
turnover changes occur early on in the initiation of AI treatment and in the ATAC, MA-17 and 
IES trials (18, 36), bone loss has translated into increased fracture rates with AI use compared to 
Tamoxifen use (25, 35).  
Body weight 
The relationship between body weight, breast cancer risk and breast cancer treatment is complex 
(37). Estrogen has long been suspected as the hormone responsible for increasing breast cancer 
risk in obese postmenopausal women (38). Aromatase resides in adipose tissue (among other 
tissues), leading to higher estrogen levels in heavier, postmenopausal breast cancer patients. This 
higher level of estrogen may thus worsen breast cancer outcome, but may be bone-protective in 
this subgroup of postmenopausal women (39). 
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The adjuvant use of adjuvant AIs have increased the concern about long-term bone health and 
fracture risk (40). Considering the bone protecting effect of estrogen (41) and the hypothesis that 
concentrations of estrogen differ among lean and obese women, it is important to investigate bone 
health in accordance with BMI (39). Endocrine therapies for breast cancer are not given by weight- 
or body-surface-area–related dosing: currently one standard dosage applies to all patients (42). 
On the other side of the spectrum, low body mass index (BMI) has long been associated with an 
increased risk of fracture (43). The fracture risk associated with low BMI (<20 kg/m2) is the 
strongest for hip fracture and independent of age, sex and BMD (43). 
In the post-menopausal breast cancer patient population, there is marked variation in BMI. The 
increased fracture risk in the lean patient, and the potential protective effect of estrogen in obese 
patients, may thus influence the outcome of BMD changes in patients on AIs.  
Vitamin D 
Vitamin D is essential for the maintenance of the human skeleton (44, 45). Wide variability in 
vitamin D levels occurs due to differences in geographic location, season, sun avoidance 
behaviours, sunscreen use, increasing age and skin pigmentation, obesity, and other lifestyle 
factors (46) . The normal 25(OH)D values remain vague (47, 48). The International Osteoporosis 
Foundation recommends a desirable 25(OH)D serum level of 30 ng/mL or above (47).  
Deficiency in Vitamin D can cause secondary hyperparathyroidism, high bone turnover, low bone 
mineral density and mineralization defects. Insufficiency can be a significant risk factor for 
osteoporosis (44) and could contribute to an increased fracture risk (34). 
Vitamin D deficiency is very common among the general population, especially the elderly, (28) 
with up to 88% of post-menopausal breast cancer patients having levels <30 ng/mL (49). Adequate 
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dietary calcium and vitamin D intake is important for maintaining BMD, but supplementation 
alone is not sufficient to prevent the accelerated bone loss that occurs during AI therapy (43). 
Vitamin D repletion to a target threshold of >40 ng/ml can have a protective effect on bone loss 
among low-risk patients on AI treatment (34). Vitamin D level is currently not measured in a 
standard fashion, prior to initiation of AI therapy but is strongly recommended if resources allow 
(50).  
Guidelines for initiation of bone therapy for surgeons prescribing aromatase inhibitors  
The importance of maintenance of bone health during adjuvant breast cancer therapy has led to the 
formulation of multiple guidelines regarding the need for bone specific protection in the setting of 
AI therapy. These guidelines are very similar in their assessment of risk and recommendations (30, 
40, 51). Bone-specific protection therapy with bisphosphonates as first line option is indicated in 
all women with a baseline bone mineral density in the osteoporotic range (T-score  -2.5SD below 
norm) and should be continued for the duration of AI therapy.   
Patients with baseline BMD in the osteopenic range, i.e. a BMD T-score between -1 and -2.5 below 
norm, also qualify for bone specific protection if additional risk factors for bone loss are identified 
at baseline or if they display accelerated bone loss during follow-up.  
Recommended calcium supplementation in postmenopausal women is a total daily intake of 1200 
mg (dietary AND supplementation). Supplementation per se should not exceed 600 mg daily. 
Recommended daily Vitamin D supplementation is 800 – 2000 IU. 
Intravenous bisphosphonate therapy such as Zoledronic Acid is currently regarded the gold 
standard during adjuvant breast cancer therapy with AIs (52). Oral bisphosphonates and 
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Denusomab are other potential and very useful treatment options. Biphosphonates suppress bone 
resorption. Side-effects with oral bisphosphonates are mostly limited to reversible gastro-
esophageal irritation. Severe suppression of bone turnover with osteonecrosis of the jaw (ONJ) or 
atypical fractures are very unusual side-effects and almost exclusively seen with the more potent 
intravenous preparations and with longstanding use (beyond 5–10 years of therapy) (53, 54). The 
advantage of preventing excessive bone loss and fractures with bisphosphonate therapy far 
outweigh the potential risk of these very unusual complications. 
 An adjusted protocol based on guidelines in the setting of adjuvant AI therapy for post-
menopausal breast cancer patients is illustrated in fig. 2.1 (51, 55). 
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Figure 2.1.  Recommended algorithm for bone protection in post-menopausal breast cancer 
patients, on Aromatase Inhibitors (AI). Adopted with permission of  Hadji et al (40, 51). 
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Conclusion 
The extended survival in breast cancer patients heightened interest in the side effect profile of 
therapies. The secondary aim of treatment should be to minimize morbidity for survivors and 
simultaneously maximize quality of life. In the era of personalized medicine, an early assessment 
of bone risk would facilitate individualized patient management decisions and provide an accurate 
estimate of disease outcomes and side effects. This would aid in implementation of measures to 
prevent or limit adverse events and to assist the clinician/ surgeon in early treatment modification 
to potentially avoid the side effect in this subgroup of susceptible women or to minimize harmful 
effects.  
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Abstract 
Background 
Genetics play a significant role in drug metabolism of endocrine therapy of breast cancer. These 
aspects have been studied extensively in patients on tamoxifen, but the pharmacogenetics 
of aromatase inhibitors are less established. In contrast to the protective effect of tamoxifen, 
aromatase inhibitors are linked with an increased risk for bone loss and fractures. 
Objective 
This review outlines key issues around implementation of pharmacogenetics of cytochrome P450 
and tamoxifen as a model for optimal use of aromatase inhibitors in postmenopausal women with 
estrogen receptor positive breast cancer.  
Methods 
Lessons learnt from the association between tamoxifen and CYP2D6 genotyping were applied to 
identify polymorphisms with the potential to change clinical decision-making in patients on 
aromatase inhibitors. The ability of next generation sequencing to supersede single-gene analysis 
was furthermore evaluated in a subset of breast cancer patients on aromatase inhibitors selected 
from a central genomics database. 
Results 
Methodological flaws in major randomized controlled trials and continued referral to incorrect 
results in expert consensus statements are important factors delaying the implementation of 
CYP2D6 pharmacogenetics in tamoxifen treatment.  This highlighted the importance of a clinical 
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pipeline including comprehensive genotyping, to define the target population most likely to benefit 
from aromatase inhibitor pharmacogenetics. 
Conclusion 
The clinical utility of CYP2D6 genotyping is well-established in patients at increased risk of 
tamoxifen resistance due to cumulative risk. The pharmacogenetics of CYP19A1 requires further 
clarification in terms of bone risk assessment for appropriate use in the treatment algorithm of 
high-risk patients at the onset of aromatase inhibitors. 
 
Keywords: Breast cancer; Oncology, Pharmacogenetics, Tamoxifen, Aromatase inhibitors, Bone 
health 
 
Introduction 
Breast cancer is the most common malignancy in females worldwide (1), but the incidence varies 
significantly across continents (2). This global variation may partly be ascribed to differences in 
genetic background underlying the development of breast cancer and response to treatment.  In 
South Africa, breast cancer is most prevalent among Caucasian and Asian women and the second 
most common cancer  among Black and Coloured women (3). Population differences in drug 
metabolism supports individualized breast cancer treatment to replace a one-size-fits all approach 
(4). The high level of population admixture detected in genetically divergent ancestral clusters in 
Africa provides the ideal study ground for pharmacogenetic studies (5, 6). 
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Both germline and tumour genetics contribute to distinct immuno-phenotypes defined by estrogen 
receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2) 
status. These histo-pathological parameters are assessed routinely in all breast cancer patients at 
diagnosis. Along with clinical variables such as tumour size and nodal status, assessment of ER, 
PR and HER2 aid risk stratification and are mandatory in guiding systemic treatment decisions 
(7). In patients with the most common ER-positive breast cancer, endocrine therapy has been used 
as the cornerstone of treatment for decades (8). 
Tamoxifen was the first targeted treatment used in ER-positive breast cancer, signalling the era of 
personalized medicine. Aromatase inhibitors (AIs) are currently the gold standard for treatment of 
endocrine responsive breast cancers in postmenopausal women. Several trials verified improved 
overall survival, a substantial decrease in recurrence and contra-lateral breast cancer, as well as a 
decrease in distant metastases when compared to tamoxifen (9, 10). However, in contrast to the 
protective effect of tamoxifen on bone health, AIs are associated with a significantly increased risk 
of bone loss and fractures (11). The severity of side-effects may impact on treatment compliance 
and thereby reduce treatment efficacy (12, 13). Table 3.1 lists the most common side effects 
encountered with endocrine treatment, with some overlap noted between tamoxifen and AIs in 
relation to incidence and severity. 
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 Tamoxifen Aromatase inhibitors  References 
Bone health Bone protective  Increased bone loss / 
fractures  
(11,14, 15, 16) 
Hot flashes  Frequent  Frequent  (13, 17, 18,19) 
Gynaecological 
effects  
Vaginal bleeding  Less vaginal bleeding  (17, 18) 
Thromboembolic 
events 
Increased risk Rare (18) 
Cognitive Brain 
Function 
 
Cognitive impairment in 
verbal memory and 
executive functioning 
 
Similar to Tamoxifen 
(20) 
Lipid metabolism and 
cardiovascular 
disease 
Decrease of low-density 
lipoproteins and total 
cholesterol  
Increase of low-density 
lipoproteins and total 
cholesterol 
(14, 15) 
Endometrial cancer Increased risk after long 
term use 
No increased risk (19) 
Arthralgia/myalgia Rare  Frequent  (19, 21, 22) 
 
Table 3.1:  Common side effects of tamoxifen and aromatase inhibitors. 
Evaluation of fracture risk preceding the initiation of AI-treatment is essential. Lifestyle 
adjustments such as exercise and supplementation with calcium and vitamin D have a favourable 
impact on long-term bone health (23). However, thresholds to introduce preventative therapy and 
bisphosphonates as the first therapeutic option for AI-induced bone loss differ amongst available 
recommendations (24). The risk of side effects from bisphosphonates, such as gastro-esophageal 
irritation and rarely osteonecrosis of the jaw exists, but the benefit of limiting bone loss and 
reducing fracture risk prevails with the use of these agents in high-risk breast cancer patients. 
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We recently reviewed the clinical and biochemical risk factors associated with decreased bone 
mineral density and adopted a treatment algorithm for application in resource-limited 
environments (25). The potential role of genetics in this clinical management scheme has not 
previously been explored in South African breast cancer patients. The clinical usefulness of testing 
for common single nucleotide polymorphisms (SNPs) at critical control points within metabolic 
pathways affecting bone health, would depend on their effect on gene regulation or structure. 
Differences in SNP allele frequency across ethnic groups and haplotype associations also require 
careful consideration prior to inclusion of clinically validated gene targets in treatment algorithms 
(6). 
An enhanced understanding of breast cancer pharmacogenetics has evolved over recent years. It 
has become clear that genetic heterogeneity necessitates the identification of therapeutic targets to 
decrease drug toxicity and improve compliance (4). The cytochrome P450 (CYP 450) enzyme 
system, which metabolizes 80-90% of all commonly prescribed drugs, has been studied in relation 
to both tamoxifen resistance and the AI side effect profile.  The evidence supporting genetic testing 
before therapy is still considered too weak for incorporation in oncology practice (26). However, 
continued referral to flawed results in randomized controlled trials in expert consensus 
recommendations exemplifies issues of fundamental importance in breast cancer 
pharmacogenetics (27).  The Austrian Breast and Colorectal Cancer Study Group Trial 8 (ABCSG 
8) fully validated the association between CYP2D6 genotype and increased recurrence rate or death 
in a subgroup of post-menopausal women with invasive ER positive breast cancer (28). These 
include comprehensive CYP2D6 genotyping to minimize misclassification of poor metabolizer 
status and numerous pharmacologic features know to influence endoxifen levels comprising 
tamoxifen monotherapy, dose (20mg) and duration of 5 years with annual follow-up. Studies 
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without such strict selection criteria for target group identification, which should preferably 
include consideration of concomitant prescriptions influencing enzyme activity, cannot be used to 
either support or refute the CYP2D6 hypothesis.  
Delaying the implementation of CYP2D6 pharmacogenetics despite evidence of clinical utility in 
a subgroup of patients, may have serious consequences in affected families (29).  This is an 
important consideration in South Africa, due to an increased frequency of founder mutations in 
the BRCA1 and BRCA2 tumour suppressor genes in Afrikaner, Coloured and Xhosa breast cancer 
patients (30). A risk-benefit assessment of potential cumulative effects led to recommendation of 
CYP2D6 genotyping in ER-positive breast cancer patients with defective BRCA1/2 genes or 
concomitant use of anti-depressants associated with reduced CYP2D6 activity (31).  
Acceptance that genetic information may be insufficient to predict treatment response led to the 
development of a pathology-supported genetic testing  platform for research translation in South 
Africa (32). Genetic testing service delivery is linked to the generation of a research database using 
an institutional review board approved protocol. Establishment of joint pathology and genomic 
facilities could overcome the limitations of single health disciplines and result in new models for 
data acquisition and earlier adoption of pharmacogenetic applications. The use of stored patient 
information for validation studies performed at the interface between the laboratory and clinic has 
gained acceptance as a possible alternative to randomized controlled trials, provided that patient 
selection criteria are well defined and adhered to (32). This approach was used to validate a 
microarray pre-screen algorithm as an appropriate strategy to reduce chemotherapy overtreatment 
in South African patients with early-stage breast cancer (33, 34). Over a 9-year period, after 
introduction of the Food and Drug Administration (FDA) approved MammaPrint test, more than 
100 early-stage breast cancer patients in South Africa could safely avoid chemotherapy. This was 
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confirmed by recent level 1A evidence from the prospective Microarray in Node Negative and 1 
to 3 Positive Lymph Node Disease May Avoid Chemotherapy (MINDACT) study (35,36). As 
demonstrated in this case, appropriate introduction of new companion diagnostics may outpace the 
reporting of randomized controlled trials that require lengthy follow-up for final assessment of 
clinical outcome.  
Similar to microarray-based breast cancer gene profiling, many challenges have been encountered 
in the pursuit of CYP 450  pharmacogenetics in patients receiving endocrine treatment for breast 
cancer (37, 38). Key issues addressed during incorporation of CYP2D6 genotyping in clinical 
practice (31) served as a model in this study to determine the appropriateness of CYP19A1 
genotyping in patients treated with AIs.  
Tamoxifen pharmacogenetics 
CYP2D6 metabolizes tamoxifen, a Selective Estrogen Receptor Modulator (SERM). The principal 
mechanism of action of tamoxifen is mediated by ER binding and blocking of the proliferative 
effects of estrogen on mammary epithelium. Figure 3.1 illustrates the tamoxifen-endoxifen 
pathway with the CYP 450 enzyme encoding genes, including CYP2D6, CYP2B6, CYP2C9, 
CYP2C19 and CYP3A4/5, shown at each step.  Except for CYP2D6, none of the other enzymes 
involved in tamoxifen metabolism appear to cause any meaningful differences in drug efficacy 
(39). 
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Figure 3.1: Major metabolic pathways for tamoxifen, with the key enzymes indicated at each step. 
CYP, cytochrome P450; SULT, sulfotransferase; UGT, uridine diphosphate 
glucuronosyltransferase  
 
The relationship between CYP2D6 and tamoxifen is intricate (40)(41). A defective CYP2D6 gene 
may lead to slower metabolizing of tamoxifen, and could result in a greater risk for adverse events 
and lower efficacy of drugs requiring CYP2D6 activation (42). The efficacy of tamoxifen is also 
influenced by co-prescription of CYP2D6 inhibitors such as certain Selective Serotonin Release 
Inhibitors (SSRI’s), commonly prescribed for depression and relief of hot flashes as a by-effect in 
breast cancer patients (43, 44). Polymorphic variation may furthermore lead to absence of a 
functional CYP2D6 protein in approximately 5-10% of individuals of European ancestry and 1-
2% of those of Asian and African ancestry (6, 43). The majority of CYP2D6 genotyping studies 
were performed in Caucasian patients. As the frequencies of CYP2D6 polymorphisms vary 
significantly between different ethnic groups, data from these studies cannot be extrapolated 
directly to non-Caucasian breast cancer patients (6, 45).  
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Several studies reported the association between CYP2D6 and hot flashes as a possible marker for 
treatment efficacy (13, 42, 46). The Breast International Group 1–98 (BIG1-98) study described a 
link between CYP2D6 genotype and tamoxifen-associated hot flashes (47). However, other studies 
reported conflicting results (48). This has partly been ascribed to the use of tumour-derived DNA 
extracted from formalin-fixed paraffin-embedded  tissue in the BIG 1–98 study for CYP2D6 
genotyping (40). Significant deviation from the Hardy Weinberg equilibrium (HWE) raised 
concerns about quality and accuracy of genotyping and the consequential mistakes in data 
interpretation and conclusions drawn from these results (27). The HWE defines expected versus 
observed genotype frequencies in a randomly mating population. Similar discrepancies were 
detected in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) and the Tamoxifen 
Exemestane Adjuvant Multinational (TEAM) trial (13, 49). These studies did not prove a link 
between CYP2D6 and tamoxifen outcome, but elicited severe critique about genotyping errors 
with considerable departure from HWE for the most important CYP2D6*4, causing conflicting 
results (50, 51).  
Despite the fact that CYP2D6 activity is largely dependent on polymorphic variation tested for in 
many laboratories worldwide, the American Society of Clinical Oncology (ASCO) maintains that 
data on the clinical utility of CYP2D6 pharmacogenetics is insufficient to endorse testing for 
endocrine treatment planning (26). They nevertheless recommend counselling of breast cancer 
patients treated with tamoxifen to avoid co-prescription of CYP2D6 inhibitors, which include a 
number of drugs frequently used for treatment of depression and other co-morbidities. The 
frequent co-prescription of certain antidepressants with tamoxifen may significantly impair the 
function of CYP2D6. This emphasizes the importance of appropriate eligibility criteria for 
selection of a subset of patients for whom the advantage of genetic testing offsets the risk (31). 
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The value of CYP2D6 genotyping depends on many factors, including the appropriate target 
population identified as one of the most important factors to consider in clinical outcome studies. 
Clinical utility was confirmed in the ABCSG 8 trial in a subgroup of breast cancer patients by 
comparing CYP2D6 poor metabolizers with extensive metabolizers according to different 
selection criteria (28). In this study, the observed CYP2D6 genotypes were in HWE, which is 
important to exclude genotype errors. CYP2D6 genotypes determined from tumor-derived DNA 
may be subject to inaccuracies due to loss of heterozygosity, known to affect the CYP2D6 locus 
in up to a third of breast cancers (40, 52). Chromosomal instability in breast cancer tissue at the 
CYP2D6 locus was an important source of error with use of breast cancer tissue to determine 
genotypes in previous randomized controlled trials (47, 49). Requests for retraction of BIG 1–98 
from the scientific literature due to significant methodological flaws, were unsuccessful (52, 53). 
It impacted on the interpretation of side effect profiles and delayed proof of clinical utility of 
CYP2D6-tamoxifen pharmacogenetics. It is therefore important to ensure quality control measures 
for accurate germline genotyping (44, 52) as we embark into the era of AI pharmacogenetics. 
 
Aromatase Inhibitor pharmacogenetics  
In the light of the challenges faced in the evolution of pharmacogenetics of the tamoxifen–CYP2D6 
pathway (figure 1), it is imperative to critically review the literature for genetic determinants of AI 
response and side effects. By comparison, little is known about the pharmacogenetics of AIs and 
it is unclear whether impediments similar to the use of tamoxifen will be encountered.  
AIs have replaced tamoxifen in endocrine therapy of women with ER-positive breast cancer due 
to improved outcome compared to tamoxifen (9, 54). In the post-menopause, estrogens are 
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produced by peripheral aromatization of androgen precursors to estrogen (55).  This reaction is 
catalyzed by the aromatase enzyme (CYP19) (56). Aromatase is a CYP 450 enzyme that is encoded 
by CYP19A1 located on chromosome 15q21.2. CYP19A1 has a complex structure, with a long 5’-
untranslated region that serves as the regulatory unit of the gene (57). Genetic variation could alter 
the levels of AIs available to inhibit aromatase and as such influence treatment efficacy and side 
effects such as bone loss (57).  
The profound suppression of estrogen production by AIs has intensified study into the potential 
deterioration of bone quality and subsequent increase of fractures (58). Estrogen is vital in 
maintaining bone structure, and plays a crucial role in the development of postmenopausal 
osteoporosis, a systemic bone disease characterized by alterations in bone quality, leading to 
fragility and fracture risk (59). The pathogenesis of osteoporosis includes multiple genetic and 
environmental risk factors. Alterations in genes involved in estrogen metabolism, such as 
CYP19A1, CYP11A1, 17-alpha-hydroxylase/17,20-lyase (CYP17), T-Cell Leukemia/Lymphoma 
1A (TCL1A) and estrogenic response (ESR1) genes are potential contributors to the abnormal 
pathophysiology of bone (60-63). 
CYP19A1 and bone effects 
 The effects of genetic polymorphisms in the CYP19A1 gene have been studied most extensively 
in breast cancer, prostate cancer and osteoporosis (59, 64). Susceptibility to side effects from AI-
treatment differs  between patients as a result of individual and ethnic variability in genetic traits 
(63, 65, 66). This supports the need for identification of biomarkers predicting clinical benefit and 
limitation of drug toxicity (65). Copy number variants and allelic variations of CYP19A1 between 
population groups justify investigation into the gene effects on side-effect profiles and drug 
efficacy between subgroups taking AIs (65). The mechanism at the core of the association between 
Stellenbosch University  https://scholar.sun.ac.za
47 
 
CYP19A1 alleles and bone mass is still unclear.  A number of polymorphisms in the CYP19A1 
gene is associated with alterations in steroid hormone levels, aromatase activity, bone mineral 
density and risk of fracture (67). These polymorphisms may impact on a predisposition to skeletal 
effects from AIs leading to substantial variances in bone loss among patients (60). 
Some studies observed no difference in treatment-related adverse effects when stratified according 
to CYP19A1 genotypes for SNPs rs10046, rs4646 and rs700519 (68, 69). Napoli and colleagues 
observed that women with the AA genotype for CYP19A1 rs700518 (G/A, Val80) developed 
substantial AI associated bone loss at the lumbar spine and total hip at 12 months compared to 
patients with GA/GG variants (64). CYP19A1 rs700518 is a synonymous G/A (or C/T) 
polymorphism (at position 49,316,404) in exon 3 of the gene. In the BIG 1-98 trial including 
CYP19A1 genotyping, SNP rs700518 AA homozygotes or AG heterozygotes exacerbated the risk 
of adverse bone effects, compared with patients who had the GG wild-type genotype, irrespective 
of treatment with tamoxifen or letrozole (70,71). Reasons provided for this discrepancy in 
allocation of the risk-associated allele focused on differences in sample size between these two 
studies. However, these contradictory results highlight inconsistencies that can be expected for 
silent mutations or synonymous SNPs such as CYP19A1 rs700518 (Val80) due to the potential for 
chromosomal cross over events.  
CYP19A1 rs700518 was found to be in complete linkage disequilibrium with allele 7 of the TTTAn 
repeat polymorphism in intron 4, known to be involved in bone homeostasis (61). Although this 
marker is considered unlikely to be functional due to its location outside the coding region of the 
CYP19A1 gene, the allelic differences in gene expression summarized in table 2 favour potential 
clinical relevance. The influence of the TTTAn repeat polymorphism on lumbar spine bone 
mineral density difference was also assessed in response to hormone replacement therapy. A 
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higher number of TTTAn repeats were associated with higher lumbar spine bone mineral density 
and lower risk of spine fracture (62).  Breast cancer patients with shorter alleles may be prone to 
these bone-related risks, which could potentially be worsened by AI therapy.  
CYP19 repeat polymorphism alleles Effect on gene expression 
TTTA7; TTTA <9 Decrease transcription 
TTTA8; TTTA >9 Increase transcription 
3TCT del TTTA7   Decrease transcription 
 
Table 3.2 Functional effects of the TTTAn repeat polymorphism rs60271534 in the CYP19A1 
gene. 
 
 
From SNP analysis to next generation sequencing 
Genotyping of the CYP19A1 TTTAn polymorphism is complex and in contrast to high throughput 
SNP analysis, it usually requires Sanger sequencing for allelic discrimination (72, 73). This may 
be the reason why several studies used the synonymous CYP19A1 rs700518 as a tagging SNP for 
genotyping of this repeat polymorphism (71). In an attempt to clarify whether this synonymous 
SNP or the TTTAn polymorphism in intron 4 of the CYP19A1 gene is in linkage disequilibrium 
with a functional variant elsewhere in the gene as previously suggested (71), five AI-treated breast 
cancer patients formerly subjected to next generation sequencing  due to ultra-low vitamin D levels 
(data not shown), were selected from the genomics database for variant calling of the CYP19A1 
gene. Table 3.3 shows seven CYP19A1 SNPs identified in these patients and one control 
individual. The synonymous SNP rs700518 was found to be in linkage disequilibrium with other 
common SNPs (rs1065778, rs10046, rs4324076, rs1143704, rs17601241, rs2289105) with a minor 
allele frequency greater than 10%. CYP19A1 rs17601241 with a minor allele frequency of 0.08 
was only identified in one individual. This limits potential clinical utility in the context of 
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pharmacogenetics, as opposed to rare high impact variants applicable to familial risk. All of these 
SNPs except for the synonymous rs700518, occur in non-coding regions of the CYP19A1 gene. 
SNP rs10046 located in the 3’untranslated region (UTR) of the CYP19A1 gene, known to be 
associated with post-transcriptional gene regulation, was identified as the most likely functional 
variant among the 7 SNPs detected by whole exome sequencing. Indeed, in vitro studies previously 
demonstrated that this SNP is associated with a high estrogen profile, which correlates with the 
amount of tumor aromatase mRNA levels (74). SNP rs10046, together with rs727479 and rs4646, 
furthermore covers 88% of haplotype diversity in Caucasians (75, 76). In our opinion, these 
findings identify rs10046 as the best candidate SNP for validation as an additional risk factor for 
bone loss in AI pharmacogenetic studies. Additional studies which take different clinical settings 
into account, is warranted in the high risk South African population, using genotype strategies that 
include both founder mutations, underlying familial risk, as well as pharmacogenetics influencing 
clinical outcome (31,77).  
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Location dbSNP 
ID 
dbSN
P ref 
Minor 
Allele 
Frequen
cy 
Control BC1 BC2 BC3 BC4 BC5 
syn 
exon3 
rs700518 C 0,3259 T C T T C/T T T 
    412 1135 1065 17/16 54 44 
intron 3 rs1065778 A 0,3259 C C T T C/T T T 
    911 2349 2554 24/34 100 92 
intron 5 rs4324076 A 0,3672 C C A A C/A A A 
    310 724 826 3/10 30 24 
intron 6 rs1143704 A 0,3662 A A T T A/T T T 
    160 268 271 2/3 17 7 
intron 7 rs1760124
1 
G 0,0857 A G G/A G G G G 
    388 395/4
76 
877 16 34 26 
intron 7 rs2289105 T 0,3718 C C T T C/T T T 
    176 253 285 11/12 15 6 
3’ UTR 
exon 10 
rs10046 G 0,3628 G A G G G/A G G 
    670 1188 1176 21/29 79 49 
 
Table 3.3 Next generation sequencing results of the CYP19A1 gene in 5 breast cancer cases and a 
control individual. 
BC-breast cancer sample number; dbSNP-database Single Nucleotide Polymorphism 
Table 3.3 supports the findings in previous studies indicating that the functional SNP rs10046 is 
in linkage disequilibrium with the synonymous CYP19A1 rs700518. The minor G allele of rs10046 
assigned as the major allele in the standard human genome reference sequence (hg19) is the most 
common allele in some populations. Notably, the six-SNP (TTATTG) haplotype identified in all 
the vitamin D deficient breast cancer patients from three different population groups in South 
Africa, was not identified in a control individual (CCCACA). Figure 3.2 shows the alignment view 
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of next generation sequencing reads encompassing the 3’UTR SNP rs10046 in exon 10 of the 
CYP19A1 gene, identified as the functional SNP most likely to be clinically useful for future 
studies in an extended patient sample. Whole exome sequencing could not detect the TTTAn 
polymorphism due to its position outside the coding region (intron 4) of the CYP19A1 gene. Failure 
to observe the expected similar clinical association of CYP19A1 rs700518 and rs10046 occurring 
in linkage disequilibrium, impedes clinical application of the BIG 1-98 randomized control trial 
results (71). The finding that rs10046 is associated with increased risk of bone AEs in patients on 
tamoxifen, not observed for patients assigned on an AI, is clinically divergent.   
 
 
Figure 3.2: Alignment view of next generation sequencing reads encompassing the 3’UTR SNP 
rs10046 in exon 10 of the CYP19A1 gene. 
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Conclusion 
Application of breast cancer pharmacogenetics into the clinical scenario remains challenging as 
management recommendations cannot be based on genotype alone.  It requires the definition of a 
target group most likely to benefit from translation of research into a clinical management pipeline, 
as outlined in figure 3. This pathology supported genetic testing approach facilitates inclusion of 
pharmacogenetics in the treatment algorithm (78), utilizing whole exome sequencing to identify 
patients with a genetic predisposition for AI adverse bone effects. Arguments around the 
implementation of CYP2D6 genotyping at the onset of treatment with tamoxifen as part of the 
clinical work up and decision making are constantly developing (39, 66, 79). In South Africa, with 
an increased frequency of founder mutations in the BRCA1 and BRCA2 genes (30), 
CYP2D6 genotyping has already been integrated into clinical practice for high risk patients on 
tamoxifen (31).  The clinical value of incorporating AI pharmacogenetics as an additional risk 
factor for bone adverse events in post-menopausal breast cancer patients on endocrine therapy, at 
highest risk for further bone loss on long term AI therapy, merits further investigation.  
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Figure 3.3: Clinical pipeline for identification of genetically predisposed postmenopausal 
estrogen receptor positive (ER+) breast cancer patients on aromatase inhibitors with severe 
bone events despite optimal treatment. 
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Abstract 
Background 
Incorporating fragmented clinical and genomic data of individual patients into medical 
management is a major challenge. This study describes the conversion of patient information 
collated at the interface between the research laboratory and clinical practice into a comprehensive 
report for real-time service delivery.  
Methods 
Data from postmenopausal breast cancer patients treated with aromatase inhibitors (AIs) were 
entered into a central genomics resource, developed in an ongoing manner. A pathology-supported 
genetic testing algorithm was used to select patients for whole exome sequencing (WES). Results 
relevant to breast cancer diagnosis, comorbidities and treatment response were integrated into an 
adaptable report format.  
Results 
The reports generated for 101 patients at the start of AIs revealed a case with an unanticipated 
BRCA2 c.3881T>A (L1294*) mutation in the presence of MTHFR rs1801133 and rs1801131 
considered relevant to osteoporosis diagnosed at baseline. The report is presented in a summarized 
format to serve as an example of recommendations that can be provided for genetic counselling 
and clinical monitoring.  
Conclusion 
The database resource enabled integration of genomic research findings for responsive health care 
delivery, an approach rarely applied in routine clinical management. The ethical framework 
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developed for this purpose provides a sound basis for clinical intervention during and beyond the 
course of a single research project. 
 
Introduction 
In today’s data-centered medical world, patient management and research are heavily influenced 
by the availability of accurate patient information in a secure digital format. Databases developed 
for a specific disease usually contain a summary of associated comorbidities and co-prescribed 
medication, but may lack information on the genetic background of study participants (1-3). 
Development of a clinically enriched genomics database necessitates an in-depth understanding of 
the effect of individual and population genomic variation on health outcomes, disease and drug 
predisposition (4, 5). Literature curation for application of personalized medicine is a time-
consuming process that may best be achieved as part of translational research projects (4). 
In an effort to keep up with new discoveries on the relationship between disease, genetic variation 
and environmental triggers, we developed a pathology-supported genetic testing (PSGT) service 
linked to the establishment of a genomics database for research translation across diagnostic 
boundaries (5). Extension of PSGT to whole exome sequencing (WES) facilitated the 
identification and clinical interpretation of genetic risk factors of relevance to both cancer 
development and tailored therapeutic intervention in a single test (6). Lifestyle factors acting in 
combination with modifier genes or low-penetrance mutations are evaluated as part of a chronic 
disease screen, routinely applied as part of the PSGT algorithm before commencing WES (7). The 
creation of a clinically enriched patient registry allows for generation of medically meaningful 
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dynamic patient reports for real-time intervention during and beyond the duration of a single 
research project. 
The need to ensure long-term sustainability of database resources was highlighted by our first 
attempt at utilizing banked information from breast cancer patients at Tygerberg hospital. Van der 
Merwe et al.(8) integrated information of a 48-year old patient with a pathogenic BRCA2 mutation 
and the cytochrome P450 D6 (CYP2D6) poor metabolizer status into an informative report, 
provided to the treating physician. It led to a change of treatment from tamoxifen to an aromatase 
inhibitor (AI) in this case. When clinical outcome studies of the entire cohort were pursued, only 
a small proportion of patient information was available due to poor record-keeping (9). This 
hampered research progress and delayed clinical implementation dependent on defining a high-
risk patient group most likely to benefit from pharmacogenetics (4).   
Genomic data generated through research is rarely used in routine clinical decision-making. In 
response to the challenges encountered with translation of database information into clinical 
interpretation and management, three aspects relating to familial risk, treatment side effects and 
comorbidities were identified for simultaneous appraisal in South African breast cancer patients 
(7). Research data relating to all three aspects are deemed important to inform the development of 
dynamic WES reports as a clinical intervention tool for personalized treatment and monitoring of 
high-risk breast cancer patients. In this article, a representative case is used as an example to reflect 
our own experience of translating genomic research findings into clinical practice. 
Materials and Methods 
Ethics approval was obtained from the Stellenbosch University Health Research Ethics Committee 
to develop a secure online research database, in parallel with patient recruitment for a bone health 
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study at Tygerberg Hospital (project reference number S13/05/103). Study participants included 
postmenopausal women between the ages of 50-80 years with newly-diagnosed, hormone-
sensitive breast cancer, due to start endocrine therapy with AIs. All participants signed informed 
consent for WES and were given the choice for sample storage in a biobank linked to this study. 
Patients were also given the option to receive feedback on lifestyle assessment and special 
investigations performed. These included a chronic disease screen incorporated as part of the 
PSGT algorithm for WES, as previously described by van der Merwe et al. (7). The questionnaire 
initially developed for this purpose was used to document the family history, personal medical 
conditions, medication use/side effects and lifestyle factors relevant to the genes tested, after minor 
modification.  
Anthropometric dimensions were measured, and dual-energy X-ray absorptiometry used to 
quantify bone mineral density. Biochemistry testing included determination of calcium, phosphate, 
parathyroid hormone and 25 hydroxy-vitamin D levels as well as bone-specific alkaline 
phosphatase and C terminal telopeptides status. Tumor histopathology was recorded and 
immunohistochemistry of estrogen receptor (ER), progesterone (PR) and human epidermal growth 
factor receptor 2 (HER2) status documented. Results of BRCA1/2 mutation screening performed 
as part of routine clinical practice at Tygerberg Hospital (10), were also documented in the REDcap 
(Research Electronic Data capture) research database (11). It is a secure, web-based application 
used to store and update project-specific clinical and translational research data as shown in table 
4.1.  
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Schedule of assessments Baseline Follow-up 
 
Written informed consent Yes n/a 
Questionnaire administration Yes n/a 
Medical and surgical history from hospital records Yes n/a 
   
Biochemistry testing Yes No 
Bone mineral density assessment Yes Yes 
DNA extraction Yes n/a 
Sample storage for whole exome sequencing Yes n/a 
   
Data capture and input Yes Yes 
 
Table 4.1: Information entered into the databases 
Figure 4.1 illustrates the adaptation of the clinical pipeline previously described by Baatjes et al. 
(4), used to select patients for next-generation sequencing. Whole exome sequencing (WES) was 
performed according to van der Merwe et al (9) using the Ion Proton apparatus. The sequencing 
data was generated and stored at the Central Analytical Facility, Stellenbosch University. The Ion 
AmpliSeq™ Exome RDY kit was used for library construction and samples were sequenced with 
the One Touch workflow, followed by variant calling against the major allele reference sequence 
(12) to screen for deleterious variants in genes relating to bone health pathways (13)(14). 
Mutations considered to be pathogenic according to ClinVar (15), were confirmed by Sanger 
sequencing and added into the research database. It is acknowledged that the several variants 
previously associated with osteoporosis are located outside of the genomic regions covered by 
WES (15, 16). 
The information obtained from routine diagnostic workup of patients at Tygerberg Hospital and 
entered into the database at baseline were uploaded for integration with genetic research data. 
Information relevant to breast cancer diagnosis, comorbidities and treatment response were 
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extracted from the database (https://www.gknowmix.org.) and compiled into an adaptable report 
format for clinical application by the treating clinician and supporting genetic counsellor.  
 
Figure 4.1: Incorporating research generated WES findings in clinical management within an adaptable 
report, generated from the genomics database. 
 
Results 
The clinical, pathological, biochemical and genetic characteristics of ER-positive postmenopausal 
breast cancer patients at the start of AIs, are captured on an ongoing basis. Figure 4.2 illustrates 
study enrollment and attrition of the cohort. Routine testing for familial breast cancer risk 
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previously identified a founder mutation (BRCA2 c.6449_6450insTA) in one patient included in 
the database, as well as a variant of uncertain clinical significance in another (data not shown). 
 
 
Figure 4.2: Study enrolment and attrition of the breast cancer cohort evaluated by dual-energy X-ray 
absorptiometry to quantify bone mineral density (BMD) at baseline and 12 months after initiation of AI 
treatment. 
 
WES preceded by PSGT identified the BRCA2 c.3881T>A (p.L1294*; rs80358632) mutation in a 
patient found to be a compound heterozygote for MTHFR rs1801133 and rs1801131. The 
collective information of this patient was extracted from the database and assimilated into a clinical 
management report as an illustrative example. Table 4.2 shows the patient data focused on 
identification of 1) pathogenic mutations associated with familial risk, 2) genetic underpinnings of 
biochemical abnormalities and comorbidities influenced by modifiable risk factors, and 3) 
increased risk of medication side effects/failure possibly due to genetic variation.  
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CASE PRE-WES EVALUATION PROPOSED ACTION 
   
1.DIAGNOSIS Age at breast cancer diagnosis 
(postmenopausal) 
• 68 years  
Tumor histology 
• Invasive lobular carcinoma  
Genetic counselling 
• Pathogenic BRCA2 c.3881T>A 
mutation identified in germline 
DNA 
Familial risk Family members diagnosed >50 years 
(late-onset) 
• Breast cancer, Sister; 
Pancreatic and Lung, Sister; 
Prostate, Brother; Stomach, 
Mother; Lung, Father 
Family members diagnosed <50 years 
(early-onset) 
• None reported 
Eligible for cascade testing of BRCA2 
c.3881T>A  
• Test family members previously 
diagnosed with cancer 
• Test unaffected relatives on 
maternal or paternal side of the 
family, depending on whether 
the pathogenic mutation is 
detected in the mother or father 
of the index patient 
2.PATHOLOGY Immunohistochemistry  
• Estrogen receptor-positive, 
progesterone receptor-positive, 
human epidermal growth 
factor receptor 2-negative 
(luminal-type) 
Biochemistry 
• Vitamin D 17.4 ng/ml 
(deficient)  
Bone mineral density 
Pathway analysis 
• Monitor homocysteine levels as 
a marker of folate status due to 
genetic variation detected in the 
MTHFR gene, implicated in 
both cancer risk and 
osteoporosis 
Optimize bone health 
• Increase vitamin D levels >30 
ng/ml 
• Consider calcium, vitamin D 
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Table 4.2.  Patient data integration for risk management in a representative case report using a 3-                
pronged approach to whole exome sequencing (WES), which enables simultaneous assessment of high-
moderate risk genes and low-penetrance mutations in key disease pathways for consideration of familial or 
personal risk reduction intervention. 
 
Discussion 
This study describes the development of an adaptable patient report from integrated database 
resources. The availability of genome-scale sequencing allows integration of genetic knowledge 
with disease information, comorbidities and medication side effects across health disciplines (19, 
20). The PSGT approach applied in this study permits actionable interventions on both a personal 
and family level, which requires careful consideration of established clinical guidelines applicable 
to high- moderate risk genes and low-penetrance mutations in key disease pathways. Given the lack of 
reporting guidelines for WES used in multifaceted conditions such as breast cancer (20), we 
developed an integrated clinical and genetic pipeline, to permit continued monitoring of outcome 
and medication side effects (4). WES using a three-pronged approach as presented here, is based 
• T score -3 (osteoporosis) supplementation and 
Bisphosphonates  
Lifestyle risk Body mass index: 28.3 kg/m2 
(overweight) 
Weight management 
3. TREATMENT Current 
• Hypertension and type II 
diabetes 
Completed 
• Chemotherapy 
To commence 
• Aromatase inhibitor (↑risk of 
bone loss) 
Implementation of clinical management 
pipeline (Figure 4.1) 
 
• Extended WES data analysis if 
considered clinically important 
by the referring clinician 
 
• Research: Extended 
pharmacogenetic analysis as 
appropriate 
Side effects None reported at baseline Monitoring 
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on at least one of three indications for testing, namely 1) cancer in the family that cannot be 
explained by previous genetic evaluation, 2) abnormal pathology test results known to be 
associated with gene-environment interaction and 3) treatment failure or toxicity associated with 
prescription medication. 
These benefits of genetic testing were demonstrated in the representative case. Co-existence of 
breast cancer and osteoporosis could partly be explained by detection of genetic variation in the 
MTHFR gene, previously identified as a BRCA1/2 modifier and risk factor for many chronic, non-
communicable diseases with a genetic component (7). MTHFR genotyping forms part of the PSGT 
algorithm applied by van der Merwe et al. (7) to determine eligibility for WES. 
The pathogenic BRCA2 c.3881T>A (p. L1294*; rs80358632) mutation detected by WES creates 
a premature stop codon in the ovarian cancer cluster region in exon 11. Mutations in this gene 
region were previously identified in families with multiple types of cancer among first-degree 
relatives of BRCA2 mutation carriers (21).  The finding was consistent with the breast, prostate, 
pancreas and stomach cancers diagnosed at an advanced age, in 5 first-degree relatives of the 
patient studied. This familial risk profile did not fulfil the standard BRCA1/2 testing criteria of the 
institute at the time of breast cancer diagnosis, nor meet the minimum of 15 points signifying a 
10% likelihood of detecting a pathogenic mutation according to the updated Manchester scoring 
system (22). Although the BRCA2 mutation was detected at a relatively advanced age in the 
patient, the potential value to the extended family would not have come under the attention for 
genetic counselling, without WES. This unanticipated genetic finding was communicated to the 
genetic counsellor for return of research results, to the individual patient (23). 
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While this study presented a single example as proof of concept for the value of WES preceded by 
PSGT, the expansion of the onco-genomic research database within a real-life clinical setting 
allows for continuation of future comparative effectiveness studies centred on an ethical 
framework. WES using a three-pronged approach as presented here, requires careful consideration 
of multiple factors, including clinician education and policy development towards future adoption 
of personalized medicine (7, 18).  
 
Conclusion  
Adaptable reports generated from the genomics research database embedded within routine health 
care delivery, augment personalized patient care and supplement the clinician and counsellor’s 
decision-making process.   
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Abstract  
Purpose 
Osteoporosis (OP) risk factor assessment and bone mineral density (BMD) testing are frequently 
omitted at baseline in AI studies, which may lead to misinterpretation of AI associated bone loss. 
The present study describes bone health of South African postmenopausal women of 
predominantly mixed ancestry, prior to AI treatment.  
Methods 
This descriptive baseline study, nested in a prospective AI intervention study, included 
postmenopausal women with endocrine sensitive breast cancer, aged 50 to 80 years. A baseline 
questionnaire documented demographic-, medical-, lifestyle- and fracture history. Body weight 
was assessed clinically, and body composition and BMD measured via dual energy 
absorptiometry. Descriptive statistics were used to summarize the data (STATA 14). 
Results 
101 participants were recruited, with a mean age of 617 years. Near one-third (n=32) of women 
at baseline fulfilled global criteria for bone protection (BMD T-score -2SD (n=18); BMD T-score 
-1.5SD to < -2SD with risk factors (n=14). Lower body weight, body mass index (BMI), fat mass 
index and lean mass index was documented in women with OP (p <0.001). Low vitamin D was 
present in 93% of the cohort tested (n=95), whilst deficient vitamin D status (<20ng/ml) was 
documented in 52 women (55%).   
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Conclusions 
In this study, a third of postmenopausal women considered for AI therapy fulfilled international 
criteria for bone protective pharmacological intervention. This emphasizes the need for baseline 
clinical risk and BMD assessment in postmenopausal breast cancer patients considered for AIs. 
Body composition and bone health associations highlight bone fragility associated with lower body 
weight.  
Keywords  
breast cancer; osteoporosis; aromatase inhibitors; body composition 
 
Introduction 
Postmenopausal women have a significantly increased risk of developing osteoporosis, which 
relates to physiological changes in the ageing female body. Osteoporosis (OP) is a potentially 
debilitating condition with high morbidity in elderly populations especially women due to the 
increased risk of fracture, especially of the spine and hip (1). Osteoporotic fractures can cause 
severe morbidity with impairment of function and quality of life (2).  
Bone mineral density (BMD) measured by dual energy X-ray absorptiometry (DXA) is a two-
dimensional measure of mineral content in specific skeletal regions (3). It is useful for evaluation 
of BMD changes over time and to assess response to therapeutic interventions (4, 5). The risk of 
fracture increases two- to three-fold with every standard deviation (SD) decline in BMD (1,6).  
Endocrine treatment is indicated for estrogen receptor (ER) positive breast cancers. Tamoxifen, a 
selective estrogen receptor modulator has been used in the treatment of endocrine responsive breast 
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cancer for several decades (7). It protects against accelerated postmenopausal bone loss, as it 
maintains selective estrogenic effects on skeletal tissue (8).  Currently, aromatase inhibitors (AIs) 
are the gold standard in the treatment of endocrine sensitive breast cancer with an improved clinical 
outcome compared to Tamoxifen (9, 10).  
Estrogen is integral in bone metabolism with a multidimensional role in the pathogenesis of 
postmenopausal OP (11). In postmenopausal breast cancer patients, AIs further decrease the 
already low circulating and tissue levels of estrogen by inhibition of the aromatase enzyme (12, 
13). Numerous studies have documented accelerated bone loss and heightened fracture risk in 
postmenopausal women on AI therapy. The most pronounced loss is noted in the first two years 
of AI treatment and in early menopause (< 4 years). AI therapy predominantly affects the axial 
skeleton (7, 9).   
Many conventional risk factors for the development of OP have been identified in the general 
population (14). Age, sex, genetic predisposition and ethnic origin represent the most important 
non-modifiable risk factors. Modifiable factors such as low body weight, a sedentary lifestyle, 
poor calcium nutrition and deficient vitamin D levels, smoking and alcohol excess, may also 
significantly impact on bone density. Body weight is one of the most important determinants of 
BMD at most skeletal sites in women of all ethnicities (14, 15).  
In randomized controlled trials of AIs, the baseline state of BMD was not always reported. The 
conventional risk factors for fracture were not quantified and the prevalence of osteoporotic 
fractures (an important risk factor for development of incident fractures) prior to AI therapy 
remains unknown (16). The presence of conventional risk factors for osteoporosis and baseline 
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BMD must be considered to accurately calculate the excessive fracture risk attributable to AI 
therapy per se.  
The present study describes the baseline bone health status, prior to initiation of Aromatase 
Inhibitor therapy, of a multi-ethnic postmenopausal women cohort with endocrine responsive 
breast cancer, resident in the Western Cape Province of South Africa.  This study is nested within 
a cohort study aiming to prospectively examine the impact of AIs on bone health. The associations 
between BMD and body composition as well as certain lifestyle factors, known to potentially 
adversely affect bone mineral status, will be examined.  
Methods  
Study Population  
This descriptive study, nested within a larger prospective cohort study was conducted at the tertiary 
breast clinic of Tygerberg Hospital, affiliated to the University of Stellenbosch. Postmenopausal 
women with newly diagnosed, histologically confirmed endocrine sensitive breast cancer, stage 0-
III were eligible for study entry. All women were between 50 to 80 years of age and were 
consecutively enrolled from August 2014 until February 2017. Race determination was made by 
self-declaration. Patients were excluded if they had known metabolic bone disease, if they suffered 
from any disease (other than breast cancer), or were taking medication known to adversely affect 
BMD. The research complied with the World Medical Association Declaration of Helsinki (ethical 
principles for medical research involving human subjects). The study was approved by the Ethical 
Review Board of the Faculty of Medicine, University of Stellenbosch (S13/05/103).   
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Demographics  
A demographic questionnaire was administered at baseline and included questions related to age, 
family medical history, personal health, lifestyle, reproduction and falls and fractures. Lifestyle 
questions included the use of alcohol (abstain, 1-7 units per week or >7 units per week), smoking 
(ever, current or never) and activity level (nil, in-house only or in-house and outdoors). The use of 
progesterone-only hormonal contraception and years since menopause (YSM) were documented.  
A history of prior fragility fractures, fall propensity indicated by falls in the last year and prolonged 
immobilization (>1 month) (14) was obtained. The medical, pharmacological and surgical history, 
as well as pathological information of the tumor, were collected at baseline.  
Anthropometry  
Basic anthropometric measurements including weight (in light clothing without shoes), height, 
waist (at level of umbilicus) and hip circumference (largest gluteal area), were taken. Body mass 
index (BMI) values were divided into weight categories (low/normal, overweight, obese and 
morbidly obese) according to the World Health Organisation (WHO) classification (17).  
Densitometry 
The DXA Hologic Discovery-W, S/N 70215; software Version 13.1 was employed in this study 
to measure BMD and body composition. A spine phantom was scanned daily to determine the 
intrinsic coefficient of variation of the machine. During the course of the study, coefficients of 
variation for BMD were < 1.5%.  A single trained DXA technician (MM Conradie) performed 
scans on all study subjects and the intra-operative variation was found to be below 1% for all 
skeletal sites.  
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Body composition 
Whole body DXA was used to measure and calculate total fat percentage, fat mass index (FMI), 
lean mass index (LMI), appendicular skeletal muscle mass as well as an android/gynoid fat ratio. 
Fat mass and lean mass measured by DXA are normalized for height (just like BMI) to calculate 
a fat mass index (fat/height2), a measure of obesity and a lean mass/height2 as an index of total 
body muscle mass. The appendicular skeletal muscle mass normalised for height2, is a good 
surrogate marker of sarcopenia, if found to be low. No local normative data for DXA measured 
body composition exist. The National Health and Nutrition Examination Survey (NHANES) 
reference dataset was thus used, which allowed comparison of the measured indices of body 
composition of our study subjects to the NHANES normal young adult female population aged 
18-25 years with a BMI within the normal WHO range (17). In the present NHANES database, fat 
comprises approximately 38% of body weight in females at age 25 years and this value will be 
regarded as the normal reference value for our study. The fat mass index was used to categorize 
study participants into weight classes similar to those mentioned for BMI (low/normal fat, excess 
fat, obese and morbidly obese). The normal fat mass index range is 5-9 kg/m2, excess fat 9.1-13 
kg/m2, obese 13.1-21 kg/m2 and morbid obesity indicated by a FMI in excess of 21 kg/m2. LMI 
and appendicular lean mass/height2 was categorized as being 2SD below or above expected with 
the cut-off values being 12.5 kg/m2 and 4.36 kg/m2, respectively. 
Bone Mineral Density 
Femoral neck (FN), total hip (TH) and lumbar spine (LS) BMD was measured. No normative data 
for South African women of mixed or black race exist. In this study, we therefore used a white 
female reference population to calculate T-scores and to define osteopenia and osteoporosis 
subgroups for all ethnicities. The use of white women as a reference for all persons in a multi-
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ethnic study may well not be appropriate, but until these ethnic specific reference ranges become 
available in our country, it is recommended to diagnose osteoporosis in all women by using the 
uniform normative database for whites.  A lateral vertebral assessment was done to detect prevalent 
morphometric vertebral fractures.  
Biochemistry 
Early morning blood samples were drawn for the evaluation of calcium homeostasis (serum 
calcium, phosphate, parathyroid hormone (PTH) and 25-OH Vitamin D levels) and to determine 
biochemical bone turnover markers (serum bone specific alkaline phosphatase and C-terminal 
telopeptides: Beta-CrossLaps/serum assay). Commercially available assays were used according 
to the manufacturer’s protocol. 
Statistical analyses 
Data management and analysis were conducted in STATA 14. Descriptive statistics were used to 
summarize the data including baseline characteristics and outcomes. Continuous data were tested 
for normality using descriptive statistics (e.g. histograms) where normally distributed data were 
presented as means and standard deviations or as medians and interquartile ranges (IQR), for non-
normally distributed data. Categorical data were presented as proportions and 95% confidence 
intervals. The associations between biological parameters and BMD was determined using one-
way ANOVA and chi2 tests. To account for confounding, significant univariate predictors were 
included in a final multinomial logistic regression model at p<0,2. An alpha of 0.05 was considered 
statistically significant. Associations were reported as relative risks with 95% confidence intervals. 
Missing data was assumed to be missing at random and no inputting performed.  
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Results 
Clinical demographic characteristics 
From August 2014 until February 2017, 101 postmenopausal participants were recruited with a 
mean age of 617 years. Near half (n=48, 48%) of women were in the 50-59year age group, with 
only a minority of the study cohort 70 years of age and older (~10%.) Eighty-two percent of the 
study population were of mixed ancestry, in accordance with the hospital’s reference population. 
White women represented 13.4% of the total cohort and two black and three Indian women were 
included. Demographics and lifestyle data are presented in Table 5.1.   
Clinical characteristics (n=101) 
Age (years) 61  7  
• 50 – 59 yrs  48 (48) 
• 60 – 69 yrs  43 (48) 
• 70 yrs+  10 (10) 
Smoking   
• ever 42 (42) 
• current 28 (28) 
Alcohol   
• abstain  79 (79) 
• 1-7 units per week  22 (22)  
• >7 units per week  0 
Activity level  
• In-house  20 (20) 
• In-house and Outdoors  81 (80) 
Falls in last year    
• Any fall  0 
Clinical fractures   
• non-vertebral 7 (7) 
Family history of OP   
• positive 1 (1) 
Age at menopause (years) 48  5 years 
Duration of menopause (n=72) 12  8 years 
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• 0 - 4 yrs  15 (21) 
• 5 - 10 yrs  15 (21) 
• > 10 yrs  42 (58) 
Hot Flashes   
• ever  64 (63) 
Hormonal contraception (ever)   
• Depot Provera  19 (19) 
• OCP  30 (30) 
 
Table 5.1. Summary of lifestyle and menstrual data of breast cancer patients at baseline 
 
Values for age, age at menopause and duration of menopause expressed as mean  SD, rest of 
data expressed as n (%). Cohort n = 101 for all clinical characteristics tabulated unless otherwise  
specified. OCP = oral estrogen containing contraceptive preparation 
 
Near half of the study population (42%) smoked at some stage in their lives and 28% of women 
reported to be current smokers. Alcohol consumption was minimal with 79% abstaining from any 
alcohol use and no intake in excess of 7 units per week reported. Most women lead a moderately 
active lifestyle with out-of-house activities documented in 81%. No falls in the last year were 
reported amongst this relatively young cohort of postmenopausal women. Low trauma non-
vertebral fractures were documented in seven women. Only one woman reported a family history 
of osteoporosis.  
Menopause occurred at a mean age of 48  5 years, within the expected normal range (45 yrs and 
older) in the vast majority. Eight women experienced an early menopause, of which six became 
menopausal between 40–45 years of age. The duration of menopause (n=73) was short (less or 
equal to 5 years) in 23% of women. Hot flashes were reported by 64% of women at some stage 
during their menopause. Hormonal contraception was used by 49% of the cohort during their 
reproductive years, of these 19% used an injectable progesterone containing preparation only. 
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Mineral homeostasis, calciotropic hormones and biochemical bone turnover markers 
Normal vitamin D status was only documented in 7% of the cohort. Insufficient vitamin D levels 
(20-30ng/ml) were present in 38% (n=36) of the cohort, whilst deficient vitamin D status 
(<20ng/ml) was documented in 55% (n=52). Bone disease caused by vitamin D deficiency is 
usually associated with values below 10-12ng/ml. This severe degree of deficiency was only 
evident in two participants, interestingly both these women had a normal BMD. Despite the almost 
universal 25-OH-Vitamin D deficiency, only twenty-four subjects (25%) had secondary 
hyperparathyroidism, a marker of poor vitamin D nutrition and/or a negative calcium balance.  
Bone specific alkaline phosphatase and β-cross laps, biochemical parameters of bone turnover, 
were normal (95% and 97% respectively) in most women, indicative of normal bone turnover at 
baseline in this cohort of postmenopausal women. 
Body composition 
Clinical and densitometric parameters of body composition are tabulated in Table 5.2. A 
concerning 85% of our cohort were overweight, with 59% falling into the obese categories of 
WHO-BMI (17). A waist/hip ratio in excess of 0.85, indicating excess metabolic risk, was present 
in the majority (79%). Densitometric assessment of body composition was in accordance with our 
clinical assessment. The mean total body fat mass (14.6  6%) and the FMI (14.4  4.8kg/m2) were 
significantly above normal. A high FMI was documented in 89% and a FMI indicative of obesity 
was present in 61% of the cohort. 
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Clinical parameters (n = 101) 
Category 
values Measurement 
Weight (kg)  81.2   19.4 
Height (cm)  158.6  6.0 
BMI (kg/cm2)  32.4  7.8 
BMI weight categories    
• Low/normal body weight   25 kg/m2 15 (15) 
• Overweight                        25.1–29.9 kg/m2 26 (26) 
• Obesity                               30–39.9 kg/m2 42 (41) 
• Morbid obesity                  40 kg/m2 18 (18) 
Waist circumference (cm)  102.1  15.8 
Waist/Hip circumference (cm)  0.9  0.1 
• > 0.85*   79 (78) 
Densitometric parameters (n = 101) 
Category 
values Measurement 
Mean Total Body Fat Mass (%)  45  6 
• Normal   38%   6 (6) 
• Increased  > 38%   95 (94) 
Mean Fat Mass Index (FMI) (kg/m2)  14.6  4.9 
• Normal                                5 - 9 11 (11) 
• Excess fat                          9.1 - 13 30 (30) 
• Obese                               13.1 - 21 53 (52) 
• Morbid obesity              >21 7 (7) 
Mean Lean Mass Index (LMI) (kg/m2)  16.7 2.8 
• Above third centile (>2SD)   12.5 98 (97) 
• Normal range < 12.5 3 (3) 
Mean Appendicular Lean mass/height2 (kg/cm2)  7.2  5.5 
• Above third centile (>2SD)   4.36  99 (98) 
• Normal range < 4.36  2 (2) 
Mean Android/Gynoid ratio  1.0  0.1 
• Gynoid dominant fat distribution  1   44 (44) 
• Android dominant fat distribution (visceral) > 1  57 (56) 
 
Table 5.2.  Body composition in postmenopausal breast cancer patients at baseline 
Body composition evaluated clinically and with DXA. Mean values presented as means ± standard 
deviation unless otherwise specified. Cohort sub-classified into WHO weight categories based on BMI and 
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percentage of cohort with waist/hip circumference indicative of metabolic syndrome (17)(18) noted*. 
Cohort also sub-classified into Fat Mass Index classification ranges in accordance with BMI weight 
categories. LMI and appendicular lean mass/height2 divided into categories below and above the third 
centile (2SD) for specific measurement in young NHANES females. All densitometric measured categories 
defined based on NHANES data base for young normal females within normal BMI range (17) Data 
expressed as n(%) of subjects within all weight categories 
 
Lean mass appeared well maintained with a significantly lowered appendicular lean mass (< 12.5 
kg/m2) indicative of sarcopenia i.e. loss of muscle strength, only documented in 2 subjects. It is 
noteworthy that both these subjects had osteoporotic range BMD, which infers a significant 
fracture risk based on low BMD and excess fall risk due to sarcopenia. 
The clinically determined BMI and the densitometric FMI were remarkably similar in their 
classification of women within the different weight categories. In the BMI determined normal to 
low body weight category, three of the women had a FMI marginally in excess of 9 (10.3 kg/m2 
in two subjects and 10.5 kg/m2 in the third subject) and only four of the women in the obese 
category, had a FMI below 13.1 kg/m2 (1.7%). 
Bone mineral density 
Baseline BMD was assessed at the lumbar spine in all participants (n=101) and in all but one study 
participant at the femoral neck and total hip region (bilateral hip replacement in one participant) 
(Table 5.3). BMD is expressed as an absolute density in g/cm2 and the deviation from expected 
peak value for the specific individual i.e. as a T-score to determine the patient’s specific BMD 
category as either within the normal, osteopenic or osteoporotic range (19). The mean BMD at all 
the measured sites for the total cohort was within the normal range (T-scores less -1 SD below 
expected peak). 
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BMD SUBCATEGORIES Lumbar Spine 
BMD (n= 101) 
Femoral neck 
BMD (n=100) 
Total hip BMD 
(n=100) 
Absolute value g/cm2 0.982  0.171 0.780  0.119 0.913  0.142 
 T-score -0.5  1.6 -0.65  1.1 -0.2  1.1 
• Normal 58 (58) 61 (60) 75 (75) 
• Osteopenia (< −1.0 > -
2.5) 
26 (26) 32 (33) 21 (21) 
• Osteoporosis ( -2.5) 13 (13) 6 (6) 3 (3) 
• High BMD (> 2.5) 3 (3) 1 (1) 1 (1) 
 
Table 5.3. Bone Mineral Density in postmenopausal breast cancer patients at baseline 
 
Absolute BMD values and T-scores at all the measured sites are presented as means ± standard deviation 
for the total study population. The cohort is then sub-classified into WHO-BMD categories (20).Number of 
patients and percentage of study population within subgroups for all measured sites is noted. 
 
 
A concerning 50% of participants displayed osteopenia at one or more measured site i.e. BMD T-
score deviations of -1 SD or more. Only two women with osteopenia, had a BMD in keeping with 
severe osteopenia i.e. a BMD T-score between -2.0 and -2.5 SD. BMD in keeping with 
osteoporosis was present in fourteen women (14%) prior to any hormonal intervention for breast 
cancer. Osteopenia and osteoporotic range BMD were most prevalent in the axial skeleton (all but 
one study subject with osteoporosis). In this group of relatively young postmenopausal women, 
the dominant loss of bone was at the lumbar spine region. This finding is not unexpected but 
noteworthy in a population expected to commence treatment with anti-estrogenic medication. A 
supernormal BMD (> +2.5 SD) was noted in three participants (3%). 
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A lateral vertebral assessment with DXA raised the suspicion of mild morphometric vertebral 
abnormalities in 15 women. Conventional radiology with a lateral lumbosacral X-ray, excluded 
significant vertebral compression ( 20% of vertebral height) in all of these women.  
Clinical characteristics, body composition and biochemistry within BMD sub-categories (normal, 
osteopenia, osteoporosis) 
Chronological age did not significantly differ amongst the BMD categories. Years since 
menopause (YSM) increased with worsening bone profile, with a mean duration of menopause 5 
years longer in the osteoporotic BMD subgroup compared to the normal BMD subgroup. No 
significant association between YSM and the BMD subgroups was noted (p = 0.14). In all the 
patients with OP, in whom the duration of menopause was documented (n=6), YSM exceeded 5 
years. 
Body composition differed significantly amongst BMD subcategories, with significantly lower 
total body weight, BMI, FMI, total fat percentage and LMI documented in the women with OP (p 
< 0.001; Table 5.4).  The waist/hip ratio was not significantly associated with BMD subcategories 
(p=0.48). The lack of association of BMD measurements with the waist/hip ratio may indicate 
difficulty to accurately determine this anthropometric parameter in a dominantly obese population.  
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Clinical characteristics, body 
composition and biochemistry 
BMD subcategories p-
value 
 Normal 
BMD 
(n=50) 
Osteopenia 
(n=37) 
Osteoporosis 
(n=14) 
 
Clinical characteristics     
Age (yrs) 59  6 62  7 64  8 0.074 
Years since menopause (yrs) 11  9 14  3 16  6 0.14 
Body composition     
Total body weight (kg) 86.6  17.3 79.5  19.2 63.8  15.4 <0.001 
BMI (kg/m2) 34.3  6.4 31.7  8.4 25.8  6.2 <0.001 
Waist/Hip ratio 0.91  0.06 0.88  0.08 0.91  0.14 0.48 
Total body fat (%) 46.9  5.0 44.9  6.6 41.6  5.9 0.144 
FMI (kg/m2) 15.0  4.3 14.0  4.9 10.5  3.6 <0.001 
LMI (kg/m2) 17.6  2.5 16.3  2.9 14.2  1.9 <0.001 
Appendicular lean mass (kg/m2)  8.1  7.6 6.6  1.1 5.5  1.1 0.19 
Biochemistry     
Vitamin D (ng/ml) 19.8  5.8 18.9  6.3 22.1  8.4 0.290 
• Total n  49 35 11  
• Sufficient  >30ng/ml  n (%) 3 (6%) 2 (5%) 2 (18%)  
• Insufficient 20-30ng/ml  n (%) 21 (43%) 12 (34%) 3 (27%)  
• Deficient: < 20ng/ml  n (%) 25 (51%) 21 (60%) 6 (54%)  
PTH (pmol/L) 5.54  2.87 5.10  1.99 6.77  4.36 0.221 
• Total n  48 36 11  
• normal 1.6-6.9 pmol/L n (%) 36 (75%) 29 (80%) 6 (54%)  
• elevated n (%) 12 (25%) 7 (20%) 5 (46%)  
 
Table 5.4. Body composition within DXA-BMD subcategories  
All values expressed as means  SD, unless otherwise specified. Yrs = years; BMI = body mass index; FMI 
= fat mass index; LMI = lean mass index; BMD = bone mineral density. BMD subcategories refers to DXA 
BMD T-score: normal = less than 1SD below norm, osteopenia = -1 to -2.49 SD below normal and 
osteoporosis = -2.5 SD below norm. p-value significant at < 0.05 for continuous comparison normal BMD 
versus osteopenia and osteoporosis subgroups. 
 
Fifty percent of women (7/14) with baseline OP had a low/normal BMI of  25 kg/m2. The other 
half had either an overweight BMI (n=4) or were obese (n=3). No woman with morbid obesity 
Stellenbosch University  https://scholar.sun.ac.za
98 
 
was osteoporotic. Although a low/normal BMI in our cohort indicates increased risk for OP, 
overweight and obese BMI did not exclude the potential of having OP.  
The mean 25-OH-Vitamin D (p = 0.290) and PTH levels (p = 0.221) were similar in the BMD 
subcategories (Table 5.4).  Twenty-one percent of women with secondary hyperparathyroidism 
had OP, slightly higher than documented for the entire cohort (14%). Near half (45%) of women 
with OP, however, had compensatory secondary hyperparathyroidism. When comparing BMD in 
ascending PTH tertiles, a significant adverse BMD effect could not be demonstrated (p = 0.720). 
When looking at BMD subcategories at specific bone sites i.e. at the femur neck, total hip and 
lumbar spine, a similar trend was noted for clinical characteristics, body composition and 
biochemistry relationships compared to the composite BMD.  BMD at all measured sites increased 
significantly with increasing BMI based on WHO subcategories as demonstrated in figure 5.1. 
 
Figure 5.1. Bone mineral density within the WHO-BMI subcategories 
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Multinomial regression adjusting for known confounders indicated PTH (RR 1.61, 95% CI 1.15-
1.25) and LMI (RR 0.3, 95% CI 0.11-0.85) were significantly associated for OP compared to 
normal bone status (Table 5.5).  
 
Crude RR Adjusted RR 
Predictors of BMD Osteopenia Osteoporosis Osteopenia Osteoporosis 
BMI 0.95 (0.83-1.01) 0.82 (0.77-0.92) 1.14 (0.90-1.44) 1.24 (0.80-1.93) 
Fat mass index 0.91 (0.83-1.00) 0.74 (0.62-0.88) 0.87 (0.66-1.14) 0.73 (0.44-1.21) 
Lean mass index 0.82 (0.69-0.98) 0.54 (0.35-0.75) 0.70 (0.47-1.03) 0.30* (0.11-0.85) 
PTH  0.93 (0.79-1.10) 1.13 (0.92-1.38) 0.98 (0.81-1.17) 1.61* (1.15-2.25) 
 
Table 5.5. Crude versus adjusted predictors (reporting relative risk) for BMD status at baseline. 
Comparison of predictors of normal BMD. RR (95% CI), *p-value significant (adjusted only) at <0.05.   
 
Discussion 
In this study of predominantly mixed ancestry postmenopausal women, a concerning 14% had 
osteoporosis at baseline and half of the cohort were osteopenic prior to any intervention. Body 
composition, especially lean mass, was significantly associated with bone mass at all measured 
sites and the risk of being osteoporotic significantly less with increasing lean mass index (p < 
0.0001). All clinical and densitometric measures of body weight and composition were universally 
lowest in the women with OP (p < 0.001).  
Only seven study subjects had sufficient 25-OH Vitamin D levels. Compensatory, secondary 
hyperparathyroidism was documented in more women with OP (45%) compared to the rest of the 
cohort (23%).  
Osteoporosis is a critical public health issue, especially in ageing postmenopausal women. The 
addition of AIs in the endocrine treatment of breast cancer compounds the problem and could 
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adversely affect bone health. A Joint Position Statement by experts from the International 
Osteoporosis Foundation Bone and Cancer Working Group indicates that women commenced on 
adjuvant AI therapy for breast cancer, experience a two to four-fold increase in bone loss compared 
to the normal rate of bone loss with menopause (21). Clinical trials have shown an approximately 
10% increase in absolute fracture risk for women on AI therapy (13, 19). The fracture incidence 
in women with breast cancer on AI therapy was reported to be around 18-20% after five years of 
follow-up (22). This indicates that about one in five women on AI’s will sustain an AI related 
fracture. These fragility fractures result in morbidity with prolonged disability and may lead to a 
loss of independence and should be actively prevented.  
It is thus essential to delineate BMD, body composition and clinical risk factors for bone loss and 
fracture at the start of treatment in these women. This will enable appropriate risk stratification 
and allow for appropriate preventative measures as indicated. Breast cancer treatment seeks not 
only to prolong survival, but also to limit side effects (13, 23).  
BMD is a precise and reproducible measure of mineral content, determines up to 70% of bone 
strength and is viewed as the most robust indicator of fracture risk in untreated patients (3). Ethnic 
differences in bone mass and the risk of osteoporotic fracture have been described globally, but 
established data are particular to black and white populations (2, 24). 
More than 80% of our study population were of mixed ancestry, a population subgroup in whom 
bone mineral density and the prevalence of fractures are largely unknown. In the only reported 
data from South Africa on BMD in women of mixed ancestry (25), BMD measurements at both 
the lumbar (p=0.25) and femoral regions (p=0.52) were similar to whites. BMD in SA black 
women are higher at the femoral regions, but  similar or even lower at the lumbar spine, compared 
to white women (26-28). Extrapolated from densitometric studies, fracture risk is expected to be 
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similar in white women and those of mixed ancestry at all sites. Limited data suggest that South 
African black women may be protected from hip fractures, but is expected to have a vertebral 
fracture risk similar to the other ethnic groups (29, 30). No formal study looking at vertebral 
fracture prevalence in women of mixed ancestry in SA has been conducted to date and the 
prevalence of vertebral fractures in this ethnic group thus remains unknown. Such knowledge will 
facilitate prevention and management strategies for osteoporosis and consequent fragility fractures 
across all ethnic groups as well as in the post-menopausal woman treated for breast cancer (31). 
The prevalence of low BMD in more than half of our study population at baseline is concerning. 
This argues for routine bone density measurements in all postmenopausal women of mixed 
ancestry presenting with breast cancer in whom AI therapy is considered. In the majority of our 
subjects, significant bone loss was confined to the axial skeleton. This is especially concerning for 
an increased risk to sustain vertebral fracture. Guidelines have proposed different cut-offs for 
intervention based on baseline assessment of bone health in women starting AI therapy for breast 
cancer. According to the most recent global consensus recommendation, all women with a BMD 
T-score  -2 SD at any measured site, should be pharmacologically protected with bone-directed 
therapy (21). In addition, patients with a BMD T-score between -1.5 SD and -2 SD with added risk 
factors for bone loss, should also be considered for treatment. These risk factors include age above 
65 years, smoking, a family history of hip fracture or a personal history of fragility as well as low 
body weight and a longer than 3-month course of glucocorticoid therapy. FRAX (fracture risk 
assessment score), an algorithm designed to provide long-term (10-year) fracture risk, is also used 
to determine the need for active intervention in women considered for AI therapy. This algorithm 
can, however, only be used in countries where the background prevalence of fragility fractures of 
the hip is known and thus at present not an option in our patient population.                                                                                                                                 
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Based on these recommendations, eighteen of the women in our cohort (18%) warranted bone 
specific therapy based on BMD criteria per se (BMD T-score  -2 SD). Seventeen of our 
participants had a BMD T-score  -1.5 SD, but > -2 SD. The presence of one or more conventional 
risk factors for bone loss in fourteen of these women also dictated the need for active intervention 
at baseline (one risk factor, n = 6; two risk factors, n = 7; three risk factors, n =1). Near one-third 
(32%) of postmenopausal women at baseline in our study fulfilled global criteria for bone-specific 
intervention.  
Obesity, based on WHO-BMI criteria, is associated with increased peak bone mineral density, with 
higher bone mineral density in postmenopausal women and with slower rates of bone loss at both 
the hip and spine. Low body weight, also specifically studied in breast cancer cohorts, represent 
an important risk factor for low bone mineral density and even osteoporosis (4). Eighty-five 
percent of our study cohort was overweight, and although associated with significant metabolic 
adversity, this may afford bone protection. 
Fat mass has been shown to be positively associated with BMD due to increased mechanical 
loading and the release of osteogenic hormones from adipose tissue (32). In addition, after 
menopause, body fat becomes the main determinant of endogenous estrogen activity. The 
production of androgens is higher in obese than in normal weight women, and the excess body fat 
will increase adipocyte conversion of androgens to estrogen (33). In contrast, fat mass also 
produces inflammatory cytokines, which may negatively influence BMD tissue (34). Skeletal 
muscle mass or fat-free lean body mass has been consistently shown to be associated with 
increased BMD in all women due to the mechanical forces placed on bone during locomotion and 
muscle activity (4, 35). 
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In this study, all clinical and densitometric measures of body composition were significantly lower 
in women with OP (p < 0.001) and osteopenia (p < 0.001), compared to those with normal BMD 
as illustrated in Figure 5.1. A lower total body weight, BMI, FMI, total fat percentage and LMI, 
was noted in women who displayed bone loss at baseline based on a BMD T-score of – 1SD or 
lower at any site (p-value <0.001). Similar relationships between body composition parameters 
and BMD at individual skeletal sites i.e. the spine and both hip regions were documented. This 
indicates a beneficial effect of increased fat and lean mass on BMD maintenance irrespective of 
site. Prior studies have suggested a more pronounced effect of body weight on BMD in the hip 
region as a more weight-bearing site (26, 36). Our data indicate benefit and a positive correlation 
irrespective of site in accordance with another local study in community dwelling, healthy black 
and white women (27).  
Fifty percent of women with OP had a low/normal BMI of  25kg/m2 in contrast to our study 
cohort in whom 85% were obese. Low body weight is a well-established risk factor for OP in 
breast cancer patients and also documented in our study cohort. In our cohort, 85% of women were 
overweight according to WHO-BMI categories (17). This percentage exceeds the national figure 
of 68% for obesity in adult South African women as reported in the Department of Health, South 
Africa Demographic and Health Survey 2016 (37). It is noteworthy, that BMI in the overweight 
and obese categories did not preclude the possibility of OP in this cohort.  
In continuous comparison, the relationship between fat mass indices (total body fat percentage and 
FMI) and lean mass indices (LMI) with BMD measurements were similar.  In our relatively young 
postmenopausal cohort, lean mass was well maintained and above the third centile (as indicator of 
significant loss of muscle mass) in all but three study subjects. Likewise, appendicular lean mass, 
a parameter closely associated with sarcopenia and fall risk in the elderly, was normal in the vast 
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majority of our cohort (98%). Our findings indicate a significant role for lean mass in maintaining 
BMD. Measurement of this component of total body weight may be especially important in older 
women with breast cancer in whom accurate risk stratification of bone health is pertinent.  
Other conventional clinical risk factors for bone loss and OP were not significantly associated with 
BMD in our study subjects, but merit discussion. Alcohol intake was minimal amongst study 
participants with no one exceeding the recommended maximum daily intake. The women were all 
active, with 81% of the cohort reporting out-of-house activities. Univariate analysis did not 
identify active lifestyle or prior smoking to have a significant adverse impact on BMD. Although 
years since menopause (YSM) increased with declining BMD categories, the increase was not 
statistically significant. In all the women with OP, in whom the duration of menopause was 
documented (n=6), YSM did exceed five years and warrants consideration in risk stratification 
programs. 
Vitamin D insufficiency is common in the general population (13) and also reflects in our mixed 
race population. A marked seasonal variation in vitamin D3 production was noted in Cape Town, 
with very little being formed during the winter months of April through September in a study 
conducted in the late 1990’s (38).  Increased skin pigment and obesity are well known risk factors 
for decreased cutaneous vitamin D production, both present in the majority of our study subjects.   
Low vitamin D is a known risk factor for osteoporosis due to the associated negative calcium 
balance and compensatory secondary hyperparathyroidism with increased bone resorption (39, 
40). The vast majority of our study participants (93%) had insufficient or deficient vitamin D 
levels, an extremely high and concerning figure. The mean 25-OH-Vitamin D (p=0.290) did not 
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differ amongst the BMD subcategories, but this may partly be due to the almost universal Vitamin 
D insufficiency in the study cohort.  
Only a minority of women with insufficient vitamin D status had elevated PTH-levels in keeping 
with a diagnosis of secondary hyperparathyroidism. Of the 38 women with insufficient Vitamin D 
levels, eight women had elevated serum-PTH (22%). Of the 52 women with deficient Vitamin D, 
15 manifested with secondary hyperparathyroidism (29%). Twenty-one percent of women with 
secondary hyperparathyroidism had OP, a figure slightly higher than that documented for the entire 
cohort (14%). When comparing BMD in ascending PTH tertiles, no significant adverse BMD 
effect was evident (p =0.720). It is noteworthy that near half (46%) of the women with OP had 
compensatory secondary hyperparathyroidism.  
Our study had limitations. Conclusions drawn from this study are limited by the small sample size 
of 101 women. Data obtained in this cohort nonetheless do contribute to the current small 
knowledge pool regarding the baseline bone health of South African postmenopausal women with 
breast cancer considered for AI therapy.  The cohort furthermore consisted almost exclusively of 
women of mixed descent and therefore our study data cannot be extrapolated to the other ethnic 
groups in our country in whom knowledge regarding baseline bone health is also very limited. A 
strength of our study, on the other hand, is that densitometric data were obtained by making use of 
a single, very experienced densitometrist that positively impact on the validity of both our body 
composition and BMD data. 
Conclusion  
A substantial 32% of our cohort of postmenopausal women considered for AI therapy fulfilled 
criteria for bone-specific pharmacological protection. Inadequate baseline assessment of bone 
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health may have dire consequences when life-saving breast cancer therapy, with known potential 
adverse bone effects, is prescribed. This study emphasizes the absolute need for BMD and clinical 
risk assessment in all postmenopausal women of mixed race with breast cancer, considered for AI 
therapy. Ultimately, it may also inform local health policy.  
The study provides valuable information regarding the relationship between body composition 
variables and bone health of postmenopausal women of mixed ancestry. It further highlights the 
importance of lower body weight as a risk factor in the assessment of bone health. The concerning 
high percentage of Vitamin D insufficiency noted in our study cohort requires additional 
investigation. Evaluation in larger cohorts may clarify the significance and magnitude of the 
impact of insufficient vitamin D status on bone health.  
This is the first study of its kind conducted in a group of women of mixed race residing in the 
Western Cape Province of South Africa. Improved insights into ethnic variations of bone health, 
provided by studies such as ours, will enable preventive approaches to osteoporosis for post-
menopausal women on breast cancer treatment (31). Further work in this same cohort will report 
on changes in bone health during the course of AI treatment. 
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Abstract 
Background 
Significant individual variation in bone loss associated with aromatase inhibitors (AIs) emphasizes 
the importance of identifying postmenopausal breast cancer patients at high risk for this adverse 
effect. The study explores the clinical relevance of genetic variation in the Cytochrome P450 19A1 
(CYP19A1) gene in a subset of South African patients during the first year of taking AIs for 
estrogen receptor (ER)-positive breast cancer.  
Methods  
The study population consisted of ER-positive breast cancer patients on AIs, followed in real-life 
clinical practice. Body mass index (BMI) was measured and bone mineral density (BMD) 
determined at baseline and at month 12. CYP19A1 genotyping was performed using real-time 
polymerase chain reaction analysis of rs10046, extended to Sanger sequencing and whole exome 
sequencing (WES) in 10 patients with more than 5% bone loss at month 12 at the lumbar spine.  
Results 
After 12 months of AI treatment, 72 patients had completed BMD and were successfully 
genotyped. Ten patients (14%) experienced more than 5% bone loss at the lumbar spine over the 
study period. Genotyping for CYP19A1 rs10046 revealed that patients with two copies of the A-
allele were 10.79 times more likely to have an ordinal category change of having an increased 
percentage of bone loss or no increase at the lumbar spine, compared to patients with the GA or 
GG genotypes (CI of 1.771- 65.830, p=0.01). None of the 34 patients without lumbar spine bone 
loss at month 12 were homozygous for the functional CYP19A1 polymorphism. At the total hip 
region, patients with the AA genotype were 7. 37 times more likely to have an ordinal category 
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change of having an increased percentage of bone loss or no increase (CI of 1.101- 49.336, 
p=0.04).  
Conclusion 
Homozygosity for the CYP19A1 rs10046 A-allele may provide information, in addition to clinical 
and biochemical factors that may be considered in risk stratification to optimize bone health in 
postmenopausal breast cancer women on AIs.  
 
 Introduction 
Aromatase inhibitors (AIs), the gold standard for treatment of estrogen receptor (ER)-positive 
postmenopausal breast cancer (1)(2), are associated with bone loss and fracture risk. There is 
however, significant individual variation in the bone loss induced by AIs. This is related to factors 
such as age, menopausal status, years since menopause and body mass index (BMI). Individual 
vulnerability to AI side effects is unpredictable and may also be explained by diverse genetic 
profiles (3).  
The aromatase enzyme plays a critical role in bone health. Rare loss of function mutations in the 
Cytochrome P450 19A1 (CYP19A1) gene, may cause decreased bone mineral density (BMD) (4, 
5). Common functional polymorphisms may affect enzyme activity in a context dependent manner 
(6). CYP19A1 rs10046 explains 1.6% of the variance in the estradiol-testosterone ratio (7). The A 
allele of CYP19A1 rs10046 is associated with raised estrogen levels, which in turn is expected to 
be beneficial for bone health (8).  
In view of the findings quoted above and our literature curation (9), we identified rs10046 as a 
clinically useful single nucleotide polymorphism (SNP) for risk stratification in AI 
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pharmacogenetics  pending validation in ethnically diverse South African breast cancer patients. 
However, genotype association with clinical outcome does not constitute biological significance; 
therefore it is important to substantiate the statistics with biological information (10). 
The study is the first to report on the impact of genetic variation within metabolic pathways 
underlying bone health in South African breast cancer patients, during the first year on AIs. 
Methods  
Study population and design 
We prospectively evaluated postmenopausal women with newly diagnosed, histologically 
confirmed endocrine sensitive early breast cancer between the ages of 50 to 80 years. The study 
was conducted at the Tygerberg Hospital Breast Clinic in affiliation with Stellenbosch University. 
The study population was derived from a larger cohort (n=101, Chapter 5) prospectively followed 
up on AI therapy to assess bone health outcomes and included 72 postmenopausal breast cancer 
patients who were successfully genotyped at baseline and in whom BMD were measured both at 
baseline and following 12 months of AI therapy. Patients with metabolic bone disease or on 
medication known to adversely affect BMD at baseline were excluded from the study. All 
participants were treated with Anastrazole, a non-steroidal AI according to guidelines, at the time 
of diagnosis. 
Information on other clinical variables were recorded at enrolment, including age at recruitment, 
gynaecological history, weight, height, calcium and Vitamin D status, activity levels and smoking 
status. 
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Bone mineral density 
Dual energy X-ray absorptiometry (DXA); Hologic Discovery-W (S/N 70215), software Version 
13.1 was employed in this study. Femoral neck (FN), total hip (TH) and lumbar spine (LS) BMD 
were measured at baseline and month 12 on treatment. A single experienced DEXA technician 
(MM Conradie) completed scans on all subjects. Intra-operator variation was below 1% for all 
bone sites.  
Genotyping  
DNA was extracted from whole blood using the QIAGEN QIAamp® DNA Blood Mini Kit 
(Hilden, Germany). At the time of study design, candidate SNPs were identified from publications 
in the literature based on their role in AI-associated effects (9, 11). CYP19A1 rs10046 was 
genotyped using real-time polymerase chain reaction (PCR) (TaqMan® technology), extended to 
Sanger sequencing and whole exome sequencing (WES) in 10 patients with more than 5% bone 
loss at month 12. WES was performed at the Central Analytical Facility of Stellenbosch 
University, using the protocol previously described (12).  
Statistical analyses 
Data management and analysis were conducted in STATA 14.  Descriptive statistics were used 
to describe baseline characteristics and 12- month outcome data. BMD were expressed as percent 
(%) change from baseline to 12 months. Continuous data were tested for normality using 
descriptive statistics (e.g. histograms) where normally distributed data were presented as means 
and standard deviations, or as medians and interquartile ranges (IQR) for non-normally distributed 
data. Categorical data were presented as proportions and 95% confidence intervals. The 
associations between biological parameters and BMD was determined using one-way ANOVA 
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and chi2 tests. To account for confounding, significant univariate predictors were included in a 
final ordered logistic regression model at p <0.2. An alpha of 0.05 was considered statistically 
significant. Associations were reported as relative risks with 95% confidence intervals. The 
Research Electronic Data Capture (REDCap) application was used for data management (13).  
Ethics approval  
The research complied with the World Medical Association Declaration of Helsinki- ethical 
principles for medical research involving human subjects- and the study was approved by the 
Ethical Review Board of the Faculty of Medicine, Stellenbosch University (S13/05/103). 
Results 
Baseline characteristics were documented in 101 breast cancer patients (Chapter 5). Seventy-two 
of these women were successfully genotyped and underwent BMD testing at baseline and after 12 
months of AI therapy.  
No significant change in the average body weight, height or BMI of the genotyped study cohort 
(n=72) was observed over the one-year course of AI therapy. When assessing changes in individual 
BMI, ten women experienced a decrease in BMI of 3 kg/m2 or more (14% of cohort), whereas the 
BMI of only four women increased to a similar degree (6% of cohort). A change in body weight 
in excess of 5 kg after 12 months of AI therapy was observed in 26 women (decrease: n=14, 
increase n=12).   
The average absolute BMD measured at all skeletal sites for this cohort on AI therapy was 
significantly lower at month 12 compared to baseline (Table 6.1). Significant bone loss based on 
average absolute BMD was thus demonstrated for the study cohort at the lumbar spine (p <0.0001). 
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 Baseline (n=72) Month 12 (n=72) p value 
Anthropometry 
Weight (kg) 82.4  19.1 81.9  19.5 0.44 
Height (cm) 159.6  5.9 158.9  6.0 0.22 
BMI (kg/cm2) 32.5  7.8 31.8  8.8 0.33 
Bone Mineral Density (g/cm2) 
Lumbar spine  1.001 ± 0.154 0. 978 ± 0.151 < 0.0001 
Femoral neck  0.798 ± 0.116 0.779 ± 0.117 <0.0001 
Total hip  0.939  0.136 0,928  0.129 0.02 
 
Table 6.1. Comparison of clinical anthropometry and BMD at baseline and after 12 months of AI 
therapy. 
Absolute parameters are presented as means ± standard deviation for patients who were genotyped. 
 
Genotyping was performed in 72 patients and included 60 women of Mixed Ancestry, 10 
Caucasians, one Black and one Indian patient. There was no difference in genotype distribution 
and allele frequency for the CYPA1 rs10046 polymorphism in the relatively small group of 
Caucasian and Mixed Ancestry patients studied. Table 6.2 shows the genotype distribution of 
CYP19A1 rs10046 in relation to baseline clinical characteristics and ethnicity and to BMD 
measurements documented both at baseline and at month 12 of AI use. The genotype distribution 
of this polymorphism was in Hardy–Weinberg Equilibrium.  
The three genotype groups were comparable with regard to age and BMI, determined both at 
baseline and at month 12. No significant weight loss, expressed as a change in BMI, were noticed 
from baseline to month 12 in any of the three genotype cohorts.   
There was an even distribution of the CYP19A1 rs10046 GG and GA genotypes in the predominant 
Mixed Ancestry group within our study population. Of the six patients with genotype AA, 67% 
(n=4) were Mixed Ancestry patients and the other two Caucasian. 
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The absolute BMD at all the measured sites, i.e. at the lumbar spine, femoral neck and total hip 
was similar in all three genotype groups. Although not statistically significant, a clear trend 
towards lower measured BMD was observed in the heterozygous and homozygous genotype 
groups with the CYP19A1 rs10046 A allele, compared to GG homozygotes. The lowered trend 
was more pronounced at 12 months, suggestive of accentuated loss in the genotype groups with 
the CYP19A1 polymorphism. This observation was noted at all skeletal sites and equates to a 
percentage difference in absolute average BMD between the GG homozygotes and AA 
homozygotes of 4.5%, 4.9% and 7.6% at the lumbar spine, femoral neck and total hip regions 
respectively, at baseline and a difference of 6.5%, 5.3% and 8.9% at the mentioned sites at 12 
months. 
                   CYP19A1 rs10046 (n = 72) 
 Genotype GG  Genotype GA Genotype AA p-value 
 34 (47%) 32 (45%) 6 (8%)  
Clinical characteristics  
Age (yrs.) 60  5.8 61   7.3 62  9.7 0.71 
BMI (kg/m2)     
baseline 33.0 ± 7.3 32.5 ± 8.7 30.1 ± 4.2 0.70 
month 12* 32.9 ± 7.7 31.0 ± 10.2 30.3 ± 6.2 0.62 
Ethnicity 
MA (n = 60) 28  28 4  N/A 
Caucasian (n =10) 5  3  2  N/A 
Black (n = 1) 1 0 0 N/A 
Indian (n = 1) 1 0 0 N/A 
Bone mineral density (g/cm2) 
Lumbar Spine     
baseline 1.028 ± 0.154 0.976 ± 0.158 0.982 ± 0.129 0.38 
month 12 1.001 ± 0.153 0.961 ± 0.154 0.936 ± 0.132 0.44 
Femur Neck     
baseline 0.819 ± 0.123 0.781 ± 0.115 0.770 ± 0.060 0.34 
month 12 0.803 ± 0.118 0.758 ± 0.119 0.750 ± 0.071 0.24 
Total Hip     
baseline 0.961 ± 0.131 0.926 ± 0.149 0.885 ± 0.063 0.35 
month 12 0.950 ± 0.132 0.917 ± 0.132 0.861 ± 0.070 0.24 
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6.2: Clinical characteristics, ethnicity and BMD in relation to genotype distribution of CYP19A1 rs10046 
in the total genotyped study population 
BMI- body mass index; MA- Mixed Ancestry; n/a-not applicable *no significant change in BMI from baseline to 
month 12 in any of the three genotypes 
 
A statistically significant (p= 0.003) decline in absolute BMD was noted for all skeletal sites in 
the three genotype groups from baseline to month 12. The greatest absolute loss (BMD decline of 
0.046) was noted for the lumbar spine region in CYP19A1 genotype subgroup AA. The decline in 
all groups were most pronounced in the lumbar and femoral neck regions known to be rich in 
trabecular bone. This is expected as a result of reduced tissue exposure to estrogen at this early 
time point of 12 months (Table 6.3). 
BMD according to genotype Baseline Month 12 p value 
Genotype GG    
Lumbar spine 1.028 ± 0.154 1.001 ± 0.153 0.003 
Femur Neck 0.819 ± 0.123 0.803 ± 0.118 0.003 
Total Hip 0.961 ± 0.131 0.950 ± 0.132 0.03 
Genotype GA    
Lumbar Spine 0.976 ± 0.158 0.961 ± 0.154 0.0005 
Femur Neck 0.781 ± 0.115 0.758 ± 0.119 0.0001 
Total Hip 0.926 ± 0.149 0.917 ± 0.132 0.29 
Genotype AA    
Lumbar Spine 0.982 ± 0.129 0.936 ± 0.132 0.0004 
Femur Neck 0.770 ± 0.060 0.750 ± 0.071 0.19 
Total Hip 0.885 ± 0.063 0.861 ± 0.070 0.09 
 
Table 6.3. Bone mineral density measurements at different skeletal sites within the three genotype groups 
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Table 6.4 shows the change in BMD at month 12 expressed as percentage bone loss. The degree 
of bone loss at the lumbar spine and total hip region is tabulated into three bone loss categories i.e. 
no change;   5%, but significant bone loss or >5% bone loss for all genotyped patients. In the 
total study population 47% of individuals (n=34) maintained their lumbar spine bone mass with 
no significant change from baseline, 39% (n= 28) had bone loss of up to 5% and 14% (n= 10) had 
bone loss in excess of 5%.  At the total hip, 72% maintained bone mass (n=52), 19% (n=14) had 
up to 5% bone loss, whereas 8% of women (n = 6) lost more than 5% of their bone mass.  Bone 
loss at the trabecular rich lumbar region were more pronounced within the limited observation 
period of 12 months compared to the total hip region mostly comprised of cortical bone as expected 
and as alluded to before.  
The percentage bone loss for the three genotypes were also calculated at the lumbar and hip region.  
All patients with the CYP19A1 rs10046 AA genotype displayed bone loss at the lumbar spine 
region over the observation period of 12 months. The individual losses in the two CYP19A1 AA 
homozygotes among patients with more than 5% bone loss were -5.8 and -7.6% respectively (one 
Caucasian, one Mixed Ancestry). The losses in the four AA homozygotes in the up to 5 % bone 
loss group ranged between -3.2 to -4.5% (one Caucasian, three Mixed Ancestry). Only 8% (n=6) 
of the study group displayed the AA genotype. Notably, this genotype group represented 20% of 
the cohort who suffered bone loss in excess of 5% over the 12-month period of AI therapy.  
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 No bone loss  5% bone loss >5% bone loss 
      n (%)      n (%)     n (%) 
Lumbar Spine    
Total (n = 72) 34 (47) 28 (39) 10 (14) 
GG genotype (n = 34) 17 (50) 12 (35) 5 (15) 
GA genotype (n = 32) 17 (53) 12 (37) 3 (9) 
AA genotype (n = 6) 0 4 (67) 2 (33) 
Total Hip     
Total (n = 72) 52 (72) 14 (19) 6 (8) 
GG genotype (n = 34) 27 (79) 5 (15) 2 (6) 
GA genotype (n = 32) 22 (69) 7 (22) 3 (9) 
AA genotype (n = 6) 3 (50) 2 (33) 1 (17) 
Table 6.4: Proportional bone loss at month 12 at Lumbar Spine (LS) and Total Hip (TH). 
Body composition parameters including clinically determined BMI and both Fat Mass Index and 
Lean Mass Index as determined by DXA were significant predictors of baseline BMD status in the 
larger study population, of whom 72 women underwent genotyping (Chapter 5).  At the lumbar 
spine, CYP19A1 rs10046 AA homozygotes were 10.79 times more likely to have an ordinal 
category change of having an increased percentage of bone loss or no increase, compared to 
patients with the GA or GG genotypes (CI of 1.771- 65.830, p=0.01). Genotyping for CYP19A1 
rs10046 revealed that patients with two copies of the A-allele are 7,37 times more likely to have 
an ordinal category change of having an increased percentage bone loss or no increase, at the total 
hip compared to those without this allele (CI of 1.101- 49.336, p=0.04). None of the 34 patients 
without bone loss at the lumbar spine at month 12, were homozygous for the functional CYP19A1 
polymorphism. DNA sequencing in the 10 patients with more than 5% bone loss, supported these 
findings and confirmed the genotype allocation of A and G alleles using real-time PCR. WES 
Stellenbosch University  https://scholar.sun.ac.za
124 
 
demonstrated sufficient coverage to accurately detect this SNP within a greater pharmacogenetics 
and diagnostic screening context, as evidenced by the concomitant detection of a pathogenic 
BRCA2 mutation (c.582G>A) in one of these patients.   
 
Discussion 
This study describes the changes in BMD measured at baseline and after one year of AI treatment 
and its relation to genetic variation in the CYP19A1 gene. In our study cohort, the rs10046 genotype 
distribution was 46% in both the GG and GA genotype groups in the Mixed Ancestry patients 
compared to 50% and 30% for GG and GA, respectively, in the Caucasians. In the AA genotype 
group (n=6), Mixed Ancestry patients comprised 67% (n=4). The three genotype groups were 
similar in terms of age and BMI, as at baseline and no significant weight loss was evident over the 
one-year period, in any of the groups.  
Recent international consensus guidelines suggest that all women starting AI therapy should have 
a baseline clinical risk assessment of osteoporosis for individualized bone protective intervention 
(13, 14). Our baseline evaluation revealed that a third of our study population already had BMD 
findings necessitating active bone protection. Body composition was identified as the most 
important clinical predictor of baseline BMD in these women (Chapter 5). Our prospective bone 
health evaluation at month 12 of AI therapy, revealed that the average absolute BMD of the cohort 
is statistically lower than that measured at baseline, but similar amongst the genotype groups. This 
finding is in keeping with most large clinical trials reporting accelerated loss up to 7.5% annually 
(16). A statistically significant decline in absolute BMD was noted in the total cohort for all 
skeletal sites, and also within all three genotype groups from baseline to month 12. The greatest 
bone loss evaluated within the three genotype groups was noted for the lumbar spine region in 
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genotype subgroup AA (average decline of 4.5% over 12 months). The decline in all groups was 
most pronounced in the lumbar and femoral neck regions known to be rich in trabecular bone. This 
is expected as reduced tissue exposure to estrogen at this early time point of 12 months will 
predominantly affect metabolically more active trabecular bone tissue. 
A trend was noted towards a lower BMD (all skeletal sites) in groups with CYP19A1 rs10046 
GA/AA genotype compared to the GG genotype, but this was not statistically significant. Small 
patient numbers within some of the genotype groups may have limited our ability to detect 
significant differences in BMD amongst these groups and warrants further health outcomes studies 
in an extended patient cohort. 
Nearly 50% of the study cohort had significant loss of lumbar BMD. Fourteen percent of these 
women had more than 5% bone loss at the lumbar spine. At the hip, nearly a third of women had 
significant bone loss at month 12 and only six patients (8%) had more than 5% bone loss. These 
findings support the earlier loss of trabecular bone following reduced skeletal exposure to estrogen 
in postmenopausal women due to AI therapy. Furthermore, the observation in our study all patients 
with the AA genotype had significant bone loss is noteworthy.  
Although many studies support the role of functional polymorphisms in breast cancer, the 
mechanism underpinning the bone loss associated with AI therapy remains elusive (17). We 
explored the clinical relevance of CYP19A1 rs10046 as an additional tool for risk stratification in 
AI-related bone outcomes. Our results reveal that women with the CYP19A1 AA genotype are 
10.79 times more likely to have an ordinal category change of having an increased percentage bone 
loss or no increase, at the lumbar spine and are 7,37 times more likely to have an ordinal category 
change of having an increased percentage bone loss or no increase, at the total hip compared to 
those without this allele. 
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CYP19A1 rs10046 AA homozygotes may represent a population of breast cancer patients who 
could be at increased risk for bone loss with long-term AI therapy. Early intervention and close 
follow-up of bone health is indicated in these patients who may comprise a subgroup who should 
be considered for other forms of endocrine therapy. 
Our single institution study is limited by small numbers, marked by a significant degree of attrition 
in a real life clinical practice setting. Although the interval of BMD assessment at one year may 
be considered too short to experience the full impact of AIs on bone,  the majority of bone loss 
have been noted early in the course of AI therapy in several studies (17, 18). This prospective 
evaluation of bone health, performed in a predominantly Mixed Ancestry population, identified 
the CYP19A1 rs10046 A allele as conferring risk to bone loss. This conflicts with findings from 
other studies in mainly European populations.  
Discrepancies reported in pharmacogenetic studies may be attributed to background genetic 
influences, environmental factors and prescribed therapies (20). Notably, the A allele was reported 
as the minor allele in African population, while the G allele is the minor allele in most other 
populations. Further investigation is therefore required to place the clinical effect observed for a 
single SNP in a genomic context, with the aim to distinguish between true linkage and association 
resulting from shared ancestry. The genetic structure of the Mixed Ancestry population provides  
a valuable tool for admixture linkage disequilibrium mapping of pharmacogenetic markers (21). 
This is of particular relevance to the unique genetic structure of the Mixed Ancestry population of 
South Africa that clusters at positions between Africans and non-Africans.  
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Conclusion 
CYP19A1 rs10046 AA homozygotes may represent a target group most likely to benefit from 
translation of research into a clinical management pipeline for individualized risk stratification. 
WES enabled screening of the entire CYP19A1 gene simultaneously targeting other genetic 
variants previously implicated in bone health, which are scattered throughout the human genome.  
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CHAPTER 7 
 
Conclusion 
 
The high proportion of postmenopausal women of Mixed Ancestry with estrogen receptor (ER)-
positive breast cancer fulfilling international criteria for bone protective measures, was the most 
striking clinical finding of the study. International guidelines recommend accurate clinical and 
biochemical bone risk assessment in all postmenopausal breast cancer patients considered for AI 
therapy. Variability in side effects of breast cancer patients with similar clinical bone risk profiles 
can be ascribed to genetic differences, also evident in our cohort. 
 
The underlying pathophysiology of AI related bone loss entails complex interactions between 
clinical, biochemical and genetic factors and none of these aspects can be interpreted in isolation. 
Incorporation of pharmacogenetics into the clinical scenario is a major challenge which was 
addressed responsively in this study by the development of adaptable reports for continued 
monitoring, beyond a single research objective. The significant effect of CYP19A1 rs10046 in the 
homozygous state provided a glimpse into the context-dependency of enzyme activity underpinned 
by genetic variation. Though impressive, no direct association can be assumed for the 7-10 times 
increased likelihood of bone loss at the lumbar spine and hip in CYP19A1 rs10046 AA 
homozygotes. This statistical association requires further investigation with robust health outcome 
studies to validate biological significance in different clinical scenarios in the genetically diverse 
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South African population. The database resource developed in parallel to patient recruitment for 
this study would facilitate this process.  
 
Aligning clinical, biochemical and genetic information translated into adaptable patient reports 
may overcome the fragmentation between service delivery and research silos. This study merged 
multi-disciplinary research in a real-life clinical setting by utilising high throughput genotyping 
and advanced next generation sequencing technologies. Insights gained from this research, may 
inform policy development for implementation of a refined bone risk stratification strategy for 
endocrine therapy in postmenopausal breast cancer patients in South Africa.  
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